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The high prevalence of obesity is a major public health concern
worldwide. Conventional strategies have failed to provide solid solutions,
greater than 90% of individuals who lost weight by diet and exercise
eventually regained the weight (Arner and Spalding, 2010a). As such,
biological factors including genetic contributions have become the research
focus on pathogenesis of obesity and the target of effective disease control.
Central to energy homeostasis is the mechanism by which animals
regulate and/or response to fluctuation in energy intake and output. Adipose
tissues participate in metabolic regulation by serving as an energy store and
by secreting adipokines such as leptin and adiponectin. Leptin functions as
the afferent signal to the central nervous system in a negative feedback loop
that maintains homeostatic control of adipose tissue mass. Leptin gene
expression is highly correlated with cellular lipid content in adipocytes but
the transcriptional mechanisms controlling leptin expression in vivo are
poorly understood. Leptin-BAC Luciferase transgenic mice combining with
other computational and molecular techniques were used to identify
transcription regulatory elements including a CCAAT-binding protein
Nuclear Factor Y (NF-Y). The function of NF-Y in adipocyte was studied in
vitro with 3T3-L1 cells and in vivo with adipocyte-specific knockout of NF-Y.
The results showed that NF-Y binding site is essential for transcriptional
regulation of leptin and NF-Y is also an adipogenic factor important for
adipocyte development in vivo (Chapter 3 and Chapter 4).

Finally, since obesity is defined as excess accumulation of adipose
tissue, understanding developmental control of adipose tissue size and body
adiposity will aid the study on disease progress of obesity. We employed a
blastocyst complementation method where wild-type ES-cell is injected into
AZIP lipodystrophic blastocyst. The result suggested that while leptin
production adipocyte-autonomous, adipose tissue expandability and glucose
metabolism is controlled by other factors inv olving other cell types in
adipose tissues and/or other organs (Chapter 5). In sum, the thesis identifies
adipocyte specific quantitative and qualitative control of leptin transcription,
at the same time presents the complexity of metabolic regulation in vivo.
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CHAPTER 1: INTRODUCTION
1.1 Obesity as a Health Concern
In 2011-2012, the prevalence of obesity in the United States was
16.9% in youth and 34.9% in adults (Ogden et al., 2014). Obesity is a major
cause of morbidity and mortality in the United States. Studies show that the
risk of death rises with increasing weight. Even moderate weight excess (10
to 20 pounds for a person of average height) increases the risk of death (Calle
et al., 1999; Patel et al., 2014). It is estimated that the annual number of
deaths attributable to obesity is about 280,000 in the United States with
more than 80% of deaths in people with BMIs (body mass index, see below)
of at least 30 kg/m2 (Allison et al., 1999a). Aside from mortality rate, obesity
substantially increases morbidity and impairs quality of life, and that clinical
studies consistently show that weight loss improves health and happiness
among obese people (Allison and Pi-Sunyer, 1995). In the midst of the energy
crisis in the 70s, Hannon and Lohman expressed the cost of obesity in terms
of the total fossil energy equivalent of the food calories saved by reducing the
present degree of obesity to optimum body weight (2.3 billion pounds for the
adult population in the US) (Hannon and Lohman, 1978). Later studies have
shown that approximately 4% of direct healthcare costs are attributed to
obesity itself (Allison et al., 1999b). Across all payers, per capita medical
spending for the obese was $1,429 higher per year, or roughly 42 percent
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higher, than for someone of normal weight, summating to a total of $147
billion dollars in 2008 (Finkelstein et al., 2009).

1.2 Definition of Obesity
Obesity is defined as excessive adiposity (body fat). The historical
method for estimating adiposity was by calculating a person's buoyancy,
which was done by measuring his or her body weight under water (Ward et
al., 1978). However, this method is cumbersome, so a surrogate measure
known as the body mass index (BMI) is now routinely used. BMI (weight in
kilograms per square of height in meters) is a convenient measure and useful
for assessing the weight status of a population over time (Romero-Corral et
al., 2008). The common classification system determines whether you are
underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight
(25-29.9 kg/m2), or obese (>30 kg/m2). There are three degrees of obesity:
class 1 (30.0–34.9 kg/m2), class 2 (35.0–39.9 kg/m2) and class 3 (≥40 kg/m2)
(WHO, 2015).
However, BMI is often unreliable to assess an individual’s weight class
because it does not account for body proportion, nor does it account for the
wide variation in the nature of obesity between different individuals and
populations (Kopelman, 2000). Particularly, BMI does not distinguish
between fat and muscle mass or adipose tissue distribution (so called ‘pearshaped’ versus ‘apple-shaped’), both of which result in profound differences
2

in body metabolism. Other direct methods that measure adiposity include
air-displacement plethysmography (commercial name BOD POD) and dualenergy x-ray absorptiometry (DEXA) (Fields et al., 2002). The waist-to-hip
circumference ratio distinguishes between central obesity and other types of
obesity, and it has been suggested that waist circumference should be
measured along with BMI to adequately classify obesity-related health risk
(Cervellati et al., 2014; Wakabayashi, 2013).

1.3 Obesity as Risk Factor
Despite some shortcomings, there is a close relationship between BMI
and the incidence of several conditions caused by excess body fat. This
relationship is approximately linear for a range of BMIs less than 30 (kg/m2),
but all risks are greatly increased for those subjects with a BMI above 30 for
both genders (Willett et al., 1999). Obesity increases the risk of several
debilitating diseases, including type 2 diabetes mellitus, cardiovascular
disease, and some cancers. The condition most strongly influenced by body
weight is type 2 diabetes, where men with BMIs of 30 (kg/m2) or higher had
a sevenfold higher risk of developing type 2 diabetes, and women with BMIs
of 30 or higher had a 12-fold higher risk compared with their normal-weight
counterparts (Guh et al., 2009). Numerous studies have demonstrated a
direct association between excess body weight and coronary artery disease
and ischemic stroke, though the contribution is multifactorial (Whitlock et al.,
3

2009). Obesity is associated with cancers of the esophagus, pancreas, colon
and rectum, breast, endometrium, and kidney (Keum et al., 2015). Also,
studies have shown correlation between obesity and depression, though it is
likely that reciprocal interactions exist between the two conditions (Faith et
al., 2011). To date, the integrated effect of obesity across physical,
psychological, and social functioning as scored by a concept known as healthrelated quality of life (HRQoL) in adults and youths is an active field of
research being pursued (Jia and Lubetkin, 2005; Swallen et al., 2005). Obesity
can influence various aspects of reproduction, especially in women. Both
infertility rates and pregnancy risks increase with BMI, including both
natural and assisted pregnancies (Brewer and Balen, 2010). Encouragingly,
however, numerous studies have shown that weight loss, even 5 to 10
percent of weight, offers meaningful health benefits to the obese person
(Ben-Menachem, 2007).

1.4 The Obesogenic Environment
While the aforementioned studies were performed in the US, obesity
is no longer a problem for developed countries alone. The largest expansion
of obesity since the 1980s has occurred in developing countries in Latin
America, Oceania, North Africa, and Asia (Finucane et al., 2011). This global
upsurge of obesity is associated with the increased availability of food,
especially energy-dense items with fat and sugar, as well as sedentary
4

lifestyle from industrialization and urbanization, best described as
the “obesogenic environment” (Kirk et al., 2010). Global changes in diet and
physical inactivity have been fueled by changes in agricultural practices, food
processing, marketing, transportation, and other aspects of urban planning.
It is worth noting that obesity often co-exists with malnutrition in lowincome urban areas, presenting a complex socioeconomic problem for
policymakers (Oliver and Hayes, 2005; Pearce et al., 2007; Robert and
Reither, 2004). However, since not everyone who has unlimited access to
food develops obesity, lifestyle and environment may be necessary but
insufficient to cause obesity.
One of the confounding phenomena is that people are well aware of
and are sincerely concerned about being obese, owing to exposure of media
and health campaigns (Kassirer and Angell, 1998). However, the battle
against obesity is largely failing. At any given time of the year, an astonishing
15 to 35 percent of Americans are trying to lose weight (Horm and Anderson,
1993). Despite all the investment of a staggering amount of time, money, and
effort, greater than 90% of individuals who lost weight by diet and exercise
eventually regained the weight (Arner and Spalding, 2010a). Moreover,
recent studies have suggested that individuals possess less control over their
own weight than they themselves believed, and that biological factors and
the modern environment are the main causes of obesity (King, 2011). Thus,
understanding the physiology of obesity is critical to effective obesity control.

5

Individual differences in a common environment are reflective of
genetic contribution (FIGURE 1.1), as is established through family studies,
investigations of parent-offspring relationships, and the study of twins and
adopted children (Maes et al., 1997; Stunkard et al., 1990). These studies
estimated the heritability of obesity is 40-70%, which is slightly less
heritable than height (Farooqi and O'Rahilly, 2006). Just as nutritional
improvement has increased the mean of adult height in many populations,
environmentally-driven changes in body weight occur against a background
of susceptibility to weight gain that is determined by genetic factors (Barsh
et al., 2000; Bouchard et al., 1990; Comuzzie et al., 1996; Price and Gottesman,
1991). For instance, different inbred strains of mice respond differently to a
high-fat diet (HFD) with varying caloric intake and weight gain (West et al.,
1992). Moreover, in the presence of gene-environment interactions, the
effects of high genetic susceptibility are amplified by a high-risk environment
(Barsh et al., 2000). Several known mutations that lead to obesity in mice
have been cloned, and some homologous mutations have been identified as
rare causes of human obesity (see below). These genes and their products
provide the molecular basis for obesity and thus promising therapeutic
targets of a complex and highly heterogeneous disease. However, these are
rare and severe conditions that do not account for common forms of body
weight variation and obesity. Overall, the etiology of modern obesity arises
from interactions of multiple genes, environmental factors, and behavior,
which makes the search for obesity genes especially challenging. Recent
6

FIGURE 1.1 Potential effect of genes and environment on adiposity
assessed by body mass index. The modern “obesogenic” environment
on the right side is characterized by the increase availability of highcalorie density food and decreased need for physical activity. The
variability in BMI will depend on the genetic susceptibility to weight gain
of individuals. Note that due to gene-environment interaction, the
distribution of BMI will have a higher mean and higher standard deviation
under the high-risk obesogenic environment. Figure adopted from Energy
metabolism, fuel selection and body weight regulation (Galgani and
Ravussin, 2008).

human genome-wide studies estimate that common genetic variation
accounts for approximately 20% of BMI variation (Locke et al., 2015).
The rapid growth in the obese population in a short period of time
excludes the possibility of significant change in the population’s genetic
makeup. Therefore it is conceivable that obesity genes have long existed in
the human genomes, which now become expressed as an obese phenotype
7

under modern environmental conditions. Several explanations for the
existence of obesity genes have been proposed. If genetic predisposition to
energy efficiency conferred a fitness advantage, the genes that enhanced
energy storage (as body fat) and avoided energy expenditure would likely be
favored by selection. Individuals with alleles of these “thrifty genes” (Neel,
1962) that favored efficient fat deposition would then survive subsequent
famines, whereas those individuals with alleles that were inefficient would
not survive. This view is supported by observations of animals that deposit a
large amount of fat prior to hibernation and migration, presumably in
prediction of reduced food availability (Klaassen and Biebach, 1994; Kunz et
al., 1998; Martin, 2008; Moore and Kerlinger, 1987). In the modern
environment, where food is abundant, the consequence is that people who
carry the “thrifty” alleles more efficiently store energy by depositing
enormous amounts of fat in preparation for a famine that never comes. The
rise in obesity among different animal species living with or around humans
in industrial societies may indicate that the “thrifty” alleles are a common
survival strategy among many animal species (Klimentidis et al., 2011). It is
worth noting that because food supplies were probably always low in
preindustrial eras, the levels of obesity, even in those carrying the “thrifty”
alleles, were probably quite modest, and individuals never became obese
enough to experience the detrimental impacts of obesity on health. Others
have proposed alternative scenarios where obesity genes arise as a sideproduct of other selection forces and genetic drift (the “drifty gene”
8

hypothesis) from a neutral evolutionary process (Himmshagen, 1979;
Rothwell and Stock, 1979; Speakman, 2008, 2013).

1.5 Historical Perspectives on Energy Homeostasis
At the beginning of the 20th century, the patriarchs of physiology,
Claude Bernard and Walter Cannon, developed the concept that the internal
environment of an organism remains constant, despite frequent fluctuations
in the surrounding variables. Organisms respond to perturbations from the
external environment with counteracting forces, a process that Cannon called
“homeostasis” (Woods and Ramsay, 2007). Subsequently, animal studies by
Gasiner and Mayer demonstrated that body weight remained remarkably
constant over long periods of time, despite environmental perturbations
including diet and physical exercise (Blundell and Bellisle, 2013). It was
thought that the animals adjusted the amount of food intake in order to
maintain constant body weight. Several theories were proposed to explain
the physiological connection between regulation of body weight and feeding
behavioral control. It was proposed that the beginning and terminating of
feeding is controlled by some satiety factor, but was felt dissatisfactory in
explaining long term body weight homeostasis.
Around the same time, studies of the brain identified two discrete
neurological pathways in which the hypothalamus controls feeding behavior
in rats. Electrolytic lesions in the ventromedial hypothalamus (VMH)
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resulted in hyperphagia and profound body weight gains due to excessive fat
deposition (Hervey, 1959). Lesions in the ventrolateral hypothalamus (VLH)
resulted in hypophagia and weight loss (Bernardis and Bellinger, 1993).
Further studies showed that the “satiety center” and “feeding center” in the
hypothalamus not only control food intake, but also regulate body weight
and energy expenditure to maintain a body weight “set-point” (Keesey and
Hirvonen, 1997). Gordan Kennedy was the first to suggest that fat might
produce a signal that was sensed by the brain, where it was compared with a
target level of body adiposity; any discrepancy between the target and signal
would subsequently trigger changes in intake or expenditure that would
regulate the levels of body fat to bring its signal back in line with the target
(Kennedy, 1953). This “lipostatic” model was based on a simple negativefeedback system, yet the signal produced by adipose tissue remained elusive.

1.6 Discovery of Leptin
The existence of an appetite suppressing hormone was demonstrated
by the results of a set of parabiosis experiments (FIGURE 1.2; a technique
that allows continuous, low-volume blood exchange between two live
animals) between genetically obese (ob) and diabetic (db) mice (Coleman,
1973; Coleman and Hummel, 1969).
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FIGURE 1.2 Schematic of effects
on obese phenotypes of
parabiosis of ob, db and wild-type
mice. From these studies Coleman
inferred that it ob might encode a
secreted molecule, for which db was
the receptor. Figure adopted from
Molecular physiology of weight
regulation in mice and humans
(Leibel, 2008).

It was known that the ob and db loci are fully-penetrant autosomal
recessive mutations that produce seemingly identical phenotypes such as
obesity, hyperphagia, hyperglycemia, and hyperinsulinemia. Since these two
genes are located on separate chromosomes (ob on chromosome 6 and db on
chromosome 4), the implication was that the observed phenotype was
secondary to some yet unidentified single primary defect. Parabiosis of db
and normal mice resulted in hypoglycemia and death from starvation in the
normal mouse, but no apparent change in its db partner. In contrast,
parabiosis of ob and normal mice produced drastic a weight loss in the ob
mouse. From these results, Coleman postulated that the db mutant produces
but does not respond to a satiety factor that is missing in the ob mutant
(Coleman, 1973). Supporting this viewpoint, parabiosis of normal rats with
11

rats harboring VMH lesions or genetically obese Zucker rats (the rat version
of db), resulted in the normal partner becoming emaciated and showing no
interest in food (Harris et al., 1987; Hervey, 1959).
The cloning and characterization of the ob gene in mice showed that it
encodes leptin (leptos from Greek: thin), a 167-amino-acid protein secreted
from adipose tissue (Zhang et al., 1994). In one of the mouse models,
C57BL/6J ob/ob1J, a nonsense mutation in leptin results in the synthesis of a
truncated and nonfunctional protein. In this mutant, the level of leptin mRNA
is elevated, suggesting that expression of the gene is under feedback control
(Maffei et al., 1995a). Subsequent studies showed that plasma levels of leptin
are highly correlated with adipose tissue mass with increased plasma levels
in obese humans and several obese mouse models and decreased levels
following weight loss (Maffei et al., 1995b). Administration of leptin by
intraperitoneal injection or constant subcutaneous infusion results in a dosedependent decrease in body weight that is restricted to adipose tissue with
sparing of lean body mass in both wild-type and ob/ob mice, but not db/db
mice (Campfield et al., 1995; Halaas et al., 1997; Halaas et al., 1995;
Pelleymounter et al., 1995). These results indicate that leptin is an afferent
signal in a negative feedback loop that regulates adipose tissue mass.
Discovery of leptin provided the molecular basis for Kennedy and Keesey’s
adipostatic set-point model of body weight regulation.

12

1.7 The Central Nervous System in Regulation of Food Intake
Leptin's primary site of action is in the central nervous system
(FIGURE 1.3), in particular, the hypothalamus, where a dense population of
neurons expressing leptin receptor (encoded by Lep-R) reside (Mercer et al.,
1996; Vaisse et al., 1996). Using purified leptin protein, expression cloning
from a phage library of the choroid plexus isolated Lep-R that binds to leptin
(Tartaglia et al., 1995). The Lep-R candidate was confirmed by mapping to a
db mutant, which contains a premature stop codon resulting in abnormal
splicing (Chen et al., 1996; Chua et al., 1996; Lee et al., 1996). Positional
cloning of Lep-R showed that this gene encodes five alternative spliced forms,
but only one variant, Lep-Rb, is essential for leptin’s weight-reducing effect
and the function of other forms are quite modest compared to Lep-Rb (Li et
al., 2013). Taken together with the fact that db mice and mice with
hypothalamic lesions are leptin resistant (Halaas et al., 1995; Maffei et al.,
1995a), these findings support the conclusion that the hypothalamus is an
important site of leptin action.
Several hypothalamic nuclei, including the arcuate nucleus, VMH, LH,
DMH, and PVN express neuropeptides and neurotransmitters that regulate
food intake and energy balance. Neuropeptide Y (NPY) and its receptors
respond to the absence of leptin, whereas melanocyte-stimulating hormone
(MSH) and its receptors, melanocortin-4 receptor (MC-4R) and agoutirelated receptor (AgRP), respond to increased leptin levels (Fei et al., 1997;
Friedman, 1997; Mercer et al., 1996). Upon binding to leptin, the leptin
13

FIGURE 1.3 Summary of leptin signaling pathway. Leptin is the afferent
signal in a negative feedback loop that maintains constancy of adipose
tissue mass. Leptin is secreted from adipocytes (bottom left) at levels
correlated with body adiposity. Increased plasma leptin results in
negative energy balance, whereas decreased levels lead to positive energy
balance. Leptin acts mainly on the hypothalamus (top), via which leptin
acts to decrease food intake and modulate glucose and fat metabolism
(right). Figure adopted from Leptin and the regulation of body weight in
mammals (Friedman and Halaas, 1998).

receptor activates the downstream pathways JAK/STAT3 and PI3-kinase,
both of which are required for proper control of energy metabolism (Bates et
al., 2003; Gao et al., 2004; Hill et al., 2008; Niswender et al., 2001). Chronic
and acute dosing of leptin via intracerebroventricular (ICV) injection reduce
food intake and induce other metabolic effects at doses significantly lower
than peripheral administration (Halaas et al., 1997; Kamohara et al., 1997).
Such leptin-induced anorexia is transient and is attenuated once the adipose
14

tissue is depleted, suggesting the presence of yet undiscovered afferent
signals (Halaas et al., 1997; Montez et al., 2005).

1.8 Metabolic and Physiological Effects of Leptin
Animals treated with leptin voluntarily decrease their food intake and
induce weight loss that selectively depletes body adipose stores (Halaas et al.,
1997). Although decreased food intake is a prominent effect of leptin
treatment, the decrease in food intake alone cannot account for the metabolic
changes observed. First, pair-fed ob/ob mice that are food restricted to the
level of intake of leptin-treated ob/ob mice lose significantly less weight than
the leptin-treated mice (Levin et al., 1996). Second, while leptin-induced
weight loss is restricted to fat mass, starvation causes a loss of both lean
body mass and fat mass at a ratio that maintains body adiposity (Halaas et al.,
1997; Pelleymounter et al., 1995). Third, leptin treatment does not lead to
the compensatory drop in energy expenditure generally evident with
decreased food intake (Halaas et al., 1997). Consistently, leptin-treated ob/ob
mice showed a reduced respiratory quotient, indicating a preference for fat
oxidation over carbohydrate oxidation (Hwa et al., 1997). Overall, both leptin
replacement in genetically leptin-deficient animals and pharmacologicallyelevated leptin in wild-type animals within the physiological range have
profound consequences on energy utilization independent of food intake and
change in body weight.
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Leptin directly regulates glucose metabolism. This is evident by the
antidiabetic effect observed when ob/ob mice are treated with a low dose of
leptin that does not decrease body weight (Pelleymounter et al., 1995).
Treatment of lean animals with leptin leads to a reduction in serum glucose
level without changing insulin levels and increases glucose usage during
euglycemic clamp experiments (Sivitz et al., 1997). In type I diabetes mellitus
(T1DM, also known as insulin-dependent diabetes), since insulin is required
for the synthesis and storage of triglycerides in adipose tissue, weight gain
cannot occur in untreated T1DM, and the associated loss of body fat is
accompanied by markedly reduced plasma leptin levels. Leptin replacement
prevents the development of insulin resistance, characteristic of T1DM in
both humans and rodents (Defronzo et al., 1982; Ykijarvinen and Koivisto,
1986). Also, the phenotype was associated with normalization of hepatic
glucose metabolism and elevated plasma levels of glucagon and
corticosterone (German et al., 2010; Yu et al., 2008). Such effects are likely
mediated through the CNS, linking the known leptin signaling pathway to
control of glucose metabolism and insulin sensitivity. For instance, rescuing
Lep-R expression in the arcuate nucleus and pro-opiomelanocortin (POMC)
neurons of Lep-R deficient mice normalizes their glucose and insulin levels,
improves their hepatic insulin sensitivity, and reduces gluconeogenesis
(Berglund et al., 2012; Coppari et al., 2005; German et al., 2009; Huo et al.,
2009).
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Despite having enormous fat deposits, ob/ob mice show many of the
abnormalities seen in starved animals, including decrease body temperature,
hyperphagia, decrease energy expenditure and physical activity,
compromised immune function, and infertility (Coleman, 1978). Low plasma
leptin in ob/ob mice leads to a state of “perceived starvation,” which activates
various response programs resulting in obesity under the presence of food
(Friedman and Halaas, 1998). The striking similarity in metabolic
implications between genetic leptin deficiency and lipodystrophy (loss of
adipose tissue), despite being the complete opposites on body adiposity level,
suggests that leptin is the key factor in mediating physiological consequences
of energy imbalance (Haque et al., 2002). This is supported by the
observation that leptin supplement attenuates the physiological responses to
food restriction in mice, including changes in gonadal, adrenal, and thyroid
axes in male mice, starvation-induced delay in ovulation in female mice,
suppression of T-cell proliferation, and increase in circulating fatty acids and
ketone bodies (Ahima et al., 1996; Lord et al., 1998; Shimabukuro et al.,
1997). These findings suggested that circulating leptin is a key signal to the
brain regarding energy stores, and a fall in leptin results in the endocrine,
behavioral, and autonomic responses characteristic of starvation. The nature
of the efferent signals from the CNS that regulate metabolism in response to
leptin are not well characterized, although some evidence suggests that the
sympathetic nervous system may play a role (Dunbar et al., 1997; Elmquist et
al., 1999; Haynes et al., 1997).
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1.9 Leptin and Pathogenesis of Obesity
The role of leptin in the pathogenesis of obesity can be inferred by
measurements of plasma leptin in obese animals (Considine et al., 1996;
Maffei et al., 1995b). An increase in leptin suggests that obesity is the result
of resistance to leptin, while a low or normal level of leptin in context of
obesity suggests an underproduction of leptin. These are analogous to insulin
production in type II (insulin resistant) and type I (insulin deficient) diabetes.
The molecular basis of known mouse models with monogenic obesity
showing Mendelian inheritance have all been uncovered. The corresponding
human disorder arising from homologous or similar genetic defects have
been identified using a candidate gene approach. These genetic mutations
include leptin (Montague et al., 1997a; Strobel et al., 1998), lep-R (Clement et
al., 1998), and prohormone convertase 1 (Jackson et al., 1997), corresponding
to the naturally occurring mouse mutants ob/ob, db/db, and fat. In addition,
patients with mutations in POMC resulting in impaired melanocortin
signaling are also obese (Krude et al., 1998). These mutations are rare and all
result in severe obesity in childhood without pleiotropic developmental
syndromes. Other human obesity mutations recognized by Mendelian
inheritance have been determined for Prader-Willi, Cohen, Alstrom, and
Bardet-Biedl syndromes, all of which obesity is one of its pleiotropic features.
Using quantitative trait locus (QTL) analysis, no causative genes have been
identified for these pleiotropic syndromes (Barsh et al., 2000; Gunay-Aygun
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et al., 1997). Consistent with findings in monogenic forms of obesity, human
genome wide studies have shown that genetic susceptibility to common
obesity is mostly associated with the function of the central nervous system
(Locke et al., 2015).
It is striking how monogenic forms of obesity are all caused by either
a defect in leptin itself or leptin downstream pathways. Yet, these defects do
not account for common obesity associated with industrialized lifestyles, of
which the molecular basis remains largely unknown. Obese humans and dietinduced obese (DIO) rodents are hyperleptinemic yet do not showed
decreased food intake or increased energy expenditure, suggesting that the
pathogenesis of common obesity is leptin resistance (Considine et al., 1996;
Van Heek et al., 1997). As such, therapeutic utility of leptin as an anti-obesity
drug is limited to the rare cases of leptin deficiency and not the greater obese
population (Heymsfield et al., 1999; Paz-Filho et al., 2011).
Animal studies suggest that leptin resistance can be caused by
reduced leptin access to its target and/or altered leptin signaling. Zealand
obese (NZO) mice, a model with polygenic late-onset obesity, are resistant to
peripherally administered leptin but responsive to centrally administrated
leptin, suggesting leptin resistance is a result of impaired leptin transport
into CNS (Halaas et al., 1997; Igel et al., 1997). Hyperleptinemic obese models
AY and db/db mice have loss-of-function mutations in MC4R and lep-R
respectively, both of which block leptin signaling in the CNS (Halaas et al.,
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1997; Ste Marie et al., 2000). Mutations can lead to altered processing of
neuropeptides, or downstream intracellular signaling in the hypothalamic
nuclei can also cause obesity with high leptin levels (Jackson et al., 1997;
Naggert et al., 1995; Prada et al., 2013; Rovere et al., 1996). Study in DIO mice
demonstrated that leptin resistance evolves over the course of diet treatment,
and that both decreased access of leptin to the hypothalamus as well as
defective STAT3 activation by the leptin receptor are involved (El-Haschimi
et al., 2000). Furthermore, it has been shown that hyperleptinemia is
required for development of leptin resistance (Knight et al., 2010). On the
cellular level, chronic overstimulation of the leptin receptor and activation of
negative feedback pathways block further leptin signaling through SOCS-3, a
protein that directly inhibits leptin signaling (Bjorbaek et al., 1998; Bjorbak
et al., 2000). Moreover, expression of a constitutively active form of STAT3, a
key mediator of leptin signaling, is sufficient to induce central leptin
resistance (Ernst et al., 2009). This mechanism is analogous to blunted
insulin signaling under chronic insulin treatment mediated by IRS-1 (White,
2006).
In human studies, several groups have reported MC4R mutations
(Hinney et al., 1999; Vaisse et al., 1998; Yeo et al., 1998), which remain the
most common obesity syndrome found in 3-5% of people with BMI above 40
(Barsh et al., 2000). The studies on MC4R demonstrated an overlapping
continuum between monogenic and polygenic obesity, as it has been found
the case in three other genes, PCSK1, POMC and BDNF (Choquet and Meyre,
20

2011). Various inheritance patterns have been reported for MC4R mutations
(Farooqi and O'Rahilly, 2006), indicating that expressivity and penetrance of
the phenotype can be modulated by other genetic and environmental factors.
Together, these suggest that development of leptin resistance is likely
multifactorial, especially within the context of environment-induced obesity.
In humans, although the notion of leptin resistance is only inferred from
elevated leptin in obese individuals, it has been shown that susceptibility to
leptin resistance or leptin production and/or leptin signaling
disproportionate to energy status underlies common obesity. For instance,
lower leptin concentrations than would be expected from BMI is linked to a
predisposition to weight gain (Ravussin et al., 1997; Scholz et al., 1996).

1.10 Alternative to “Set-Point” Model
While the leptin signaling pathway provides that strongest argument
for a feedback system that maintains energy homeostasis based on energy
storage (adipose tissue), development of leptin resistance in common obesity
and increased prevalence of obesity over the past decades suggest certain
shortcomings of our understanding. In other words, if, as Kennedy and
Keesey (Keesey and Hirvonen, 1997; Kennedy, 1953), had put forth, each
body possesses an energy status “set-point” in terms of adiposity, each
individual ought to maintain his or her body weight through a negative
feedback mechanism that offsets short-term energy fluctuation. However,
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anthropological studies disprove such a system by demonstrating that
modern obesity is dependent on socioeconomic status of an individual
(Dykes et al., 2004; Poskitt, 2009) and is often associated with certain major
life events such as attending college, marrying, and immigration to Western
countries (Cluskey and Grobe, 2009; Oza-Frank and Cunningham, 2010;
Sobal et al., 2009). In Western countries, most people gain weight throughout
their life, suggesting at least age-dependent effect for an individual’s energy
“set-point” (Kuczmarski et al., 1994).
As such, a “settling-point” model was proposed from a mathematical
model for weight regulation (Payne and Dugdale, 1977), where any
imbalance between energy intake and energy requirement results in a
change in body weight. Such change, in turn, alters the maintenance energy
requirement so as to counter the original imbalance and the system would
hence be stabilized. Since there is no actual set-point or feedback signal in
the “settling point” model, altered energy status occurs whenever a regulated
variable is adjusted to balance change in an unregulated variable. This model
provides cogent explanations for the “obesogenic” environment where food
intake can be increased by external cues such as large portion size, exposure
to high density foods, frequency of dining out, as well as eating with others
(O'Keefe and Abuannadi, 2010; Rolls et al., 2007; Thornton et al., 2011). The
extent to which energy intake and expenditure are regulated appears to be
determined largely by genetic factors (Vogels and Westerterp-Plantenga,
2005; WesterterpPlantenga et al., 1996). In mice with fixed levels of plasma
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leptin, nonetheless, gained weight in response to a HFD at a rate that was
indistinguishable from wild-type animals on the same diet, and the two
groups reached an identical body weight plateau (Knight et al., 2010; Tanaka
et al., 2005). If proportional increase in leptin with weigh gain is necessary
for establishing energy balance, these animal models with artificial leptin
deficiency would be predicted to gain weight more quickly than wild-type
controls. The fact that this was not observed indicates that a leptinindependent mechanism specifies the body weight set point in animals fed a
high-fat diet. Likewise, leptin infusion fails to prevent weight gain in wildtype animals undergoing HFD treatment (Surwit et al., 2000). In aggregate,
these results are consistent with settling-point model. How energy regulation
is achieved through balancing various long and short term variables remains
an important question.
Despite its shortcomings in explaining development of obesity under
over-nutrition, the “set point” model provides a better picture for energy
regulation during starvation and deprivation. In the classical Minnesota
Experiment, food-restricted individuals over-eat to replenish the body mass
(both fat and lean) to pre-restricted level (Dulloo et al., 1996; Speakman et al.,
2011), suggesting an active regulatory mechanism in response to being
underweight. Even after energy homeostasis, which is substantially
perturbed in anorexia nervosa, recovered patients often return to premorbid
body weight (Coners et al., 1999; Hebebrand et al., 1997). On the other hand,
in both normal and overweight humans, diet-induced weight loss is resisted
23

by reduced energy expenditure (Dulloo and Jacquet, 1998; Luke and
Schoeller, 1992). Perhaps most strikingly, body fat removed by surgery is
restored within one year post-operation (Hernandez et al., 2011). In sum,
body weight and body adiposity are defended in the face of energy
deprivation, since loss of energy storage and intake due to starvation present
an immediate risk to survival. Consistently, hypothalamic targets of leptin,
including NPY, POMC, and CART neurons, are more responsive to leptin
during fasting than in the overfed or obese state (Ahima et al., 1999). Low
leptin levels induced by fasting and reduction in energy stores mediate
various physiological consequences of energy deprivation (Ahima et al., 1996;
Keim et al., 1998). As such, falls in body adiposity and leptin levels serve as
signals of negative balance from the “set-point,” which activates adaptive
response to starvation and defense against further deviation.

1.11 Regulation of Leptin Gene in Adipose Tissue
Acting as a surrogate for fat mass, plasma leptin levels are highly
correlated with adipose tissue mass in animals and humans over a very large
dynamic range (Frederich et al., 1995; Maffei et al., 1995b). Changes in
plasma leptin levels are associated with changes in leptin mRNA per
adipocyte and the levels of leptin mRNA per cell are highly correlated with
intracellular lipid content (Couillard et al., 2000; Maffei et al., 1995a). This
suggests that regulation of leptin is primarily achieved at the transcriptional
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level with only a few in vitro studies demonstrating increased leptin
secretion with insulin treatment (Barr et al., 1996; Bradley and Cheatham,
1999; Lonnqvist et al., 1997; Moreno-Aliaga et al., 2000). Small amounts of
leptin expression have been reported in brain, pituitary, stomach, mammary
epithelial cells, liver, chondrocytes and muscle, but the physiological
importance of this low level expression, if any, is unclear (Birsoy et al., 2008b;
Rosenbaum et al., 2002). Both quantitative (fat mass dependent) and
qualitative (tissue-specific) regulation of leptin gene expression is important
for its physiological role in metabolic regulation, yet little is known since the
cloning of leptin in 1994.
Leptin production is regulated by various metabolic stimuli including
positive regulator glucocorticoids (Devos et al., 1995; Slieker et al., 1996) and
proinflammatory cytokines TNF and IL-1 (Grunfeld et al., 1996; Sarraf et al.,
1997), and negative regulators include beta adrenergic agonists and cAMP
(Mantzoros et al., 1996; Slieker et al., 1996). Insulin has also been found to be
capable of modulating leptin expression (Wabitsch et al., 1996), particularly
as a suppressor during starvation where a rapid fall in leptin is
disproportional to the fall in adipocyte energy stores (Ahima et al., 1996;
Boden et al., 1996). Despite these external influences, it is likely that cellautonomous factors are the major links between adipocyte size and leptin
gene expression. Recent studies have shown that individual adipocytes
maintain idiosyncratic levels of fat accumulation and nutrient uptake during
de-differentiation and re-differentiation (Katz et al., 2014; Varlamov et al.,
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2015). Which intracellular metabolites, signaling molecules, or transcription
factors provide the necessary link is still unclear.
Further studies have been impeded by lack of a tissue culture model
for adipocytes, as leptin expression levels in preadipocyte cell lines are 1–2%
of that seen in adipose cells in situ (Macdougald et al., 1995). Interestingly,
cultured adipocytes transplanted subcutaneously can grow into fat pads,
which showed a 10-fold increase in leptin expression to a level 10–15% of
that seen in adipocytes in situ (Green and Kehinde, 1979; Mandrup et al.,
1997). These results suggest the existence of a key, unidentified, in
vivo regulatory factor, and it mandates studies of leptin expression
performed in vivo.
The proximal promoter of leptin, a 762bp region upstream to the
transcriptional start site (TSS) has been characterized by DNA sequence
analysis in both humans and mice (de la Brousse et al., 1996; Gong et al.,
1996). This region contains several transcription factor binding sites of
factors known for adipocyte functions such as the C/EBP family, Sp-1, CREB,
and SREBP-1c (He et al., 1995; Hwang et al., 1996; Mason et al., 1998).
The promoter of leptin is positively regulated through by C/EBPα (He et al.,
1995; Miller et al., 1996), and suppressed by PPARg through functional
antagonistic interaction between C/EBPa and PPARg (DeVos et al., 1996;
Hollenberg et al., 1997). However, a transgene driven by the 762bp proximal
promoter showed a lower expression than the normal physiological level and
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did not confer adipose tissue specific expression (Chen et al., 1999; Hwang et
al., 1996). This suggested that while the proximal promoter contains
sequences sufficient to drive leptin transcription using ubiquitous machinery,
additional mechanisms involving distal cis-elements and novel trans-factors
are required to confer tissue specific regulation. Suppression of leptin
transcription in other tissues remains to be explored.
In adipocytes, leptin expression is proportional to cell size, which in
turn is dependent on the amount of triglyceride stores. Several possibilities
on cell-autonomous regulation of leptin expression have been proposed. It is
known that membrane cholesterol concentration is inversely proportional to
adipocyte size and that cholesterol regulates glucose metabolism in
adipocytes via gene expression modulation (Le Lay et al., 2001). However,
manipulation of cholesterol concentration in 3T3-L1 cells, despite alteration
of many metabolic genes, does not change leptin expression (Le Lay et al.,
2001), and that membrane cholesterol composition may simply be the
adaptive response to change in cell size and mechanical strain in the cell
membrane (Khatibzadeh et al., 2012). Mechanical force itself has been
implicated in regulating adipogenesis (David et al., 2007; Sen et al., 2008;
Tanabe et al., 2004). Notably, the extracellular matrix (ECM), serving as a
scaffold of adipose tissue, is also capable of regulating physiological and
pathological responses of fat mass expansion. Up-regulation of many ECM
components results in reduced mechanical plasticity of fibrotic adipose
tissue and presents a hallmark of metabolically dysfunctional adipose tissue
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in a state of obesity (Khan et al., 2009; Sun et al., 2011). The direct
relationship and the signal transduction pathway between mechanical
strains exerted on expanding adipocytes and increased leptin expression is
unknown. Alternatively, hypoxic conditions encountered by large adipocytes
with limited oxygen diffusion can directly regulate leptin expression through
hypoxic response transcription factor HIF1α (Sun et al., 2013). Hypoxic
stress is also prominent at the tissue level in obesity as capillary density is
lower in the adipose tissue of obese humans compared with lean subjects
(Pasarica et al., 2009; Rajala and Scherer, 2003). The molecular mechanism
coordinating and connecting these different cellular responses to leptin
expression remains to be explored. Chapter 3 of this thesis presents the
identification of a distal enhancer sequence of leptin gene, and the
identification of its binding protein and subsequent functional analysis is
detailed in Chapter 4.
From the approach of genomic study, transcriptional regulation of
leptin can be considered as specific molecular programs in white adipose
tissue that coordinates as well as responds to physiological and metabolic
changes in animals. As such, comprehensive molecular characterization and
comparison of white adipose tissue from different states of ambient leptin
can elucidate specific cellular programs affected by leptin. Previous study
had utilized a microarray technique to characterize the molecular events in
white adipose tissue associating with alteration in circulating leptin levels
(Soukas et al., 2000). These results uncovered a large number of metabolic,
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inflammatory, and structural genes dysregulated with chronic leptin
deficiency (ob/ob) as well as the acute responses of fatty acid and
triglyceride metabolic pathway following leptin change. Chapter 5 of this
thesis presents an updated work of similar approach, which utilized nextgeneration-sequencing that allows unbiased molecular characterization.
Since plasma leptin level is determined by aggregated production
from all adipocytes in an animal, it remains uncertain how leptin gene
regulation within individual adipocytes rely metabolic signal at an
organismal level. Indeed, with the production of various adipokines with
hormonal functions, adipose tissues should be considered, as a whole, an
endocrine organ in addition to its classical role as a storage organ (Ahima,
2006). Indeed, as organ size control is central to mammalian development,
each species also possesses predefined body adiposity. However, prominent
heterogeneity in adipocytes from different depots and within each depot
complicates studies of adipocyte biology (Guo et al., 2004; Montague et al.,
1997b; Montague et al., 1998). In addition, two distinct processes,
hypertrophy and hyperplasia, that accompany adipose tissue expansion
during normal development and obesity (Jo et al., 2009; Sun et al., 2011),
contribute to the complexity of the issue. Therefore, understanding the
process of adipogenesis from the perspective of organ size control in
multicellular organisms is essential to elucidate regulation of the leptin gene.

29

1.12 Transcriptional Regulation of Adipogenesis
The mechanisms controlling cellularity of adipocytes in vivo is best
approached by studying adipose tissue development. Adipogenesis is
described as a two-step process: generation of committed adipocyte
precursors (or preadipocytes) from embryonic stem cells and terminal
differentiation of preadipocytes into mature adipocytes (Billon et al., 2007).
Differentiation of preadipocytes has been studied extensively in vitro, from
which several adipogenic transcription factors, such as peroxisomeproliferator activated receptors PPARγ and PPARβ and CCAAT-enhancer
binding proteins C/EBPα, C/EBPβ, and C/EBPδ, were identified (Chawla et al.,
1994; Christy et al., 1991).
Adipogenesis in vitro follows a highly ordered and well characterized
sequence of events (Rosen et al., 2000). Initially, there is growth arrest of
proliferating preadipocytes, usually achieved in cultured cell lines after
contact inhibition. This growth arrest is induced by the addition of prodifferentiation hormones into the cultured models and is followed by one or
two additional rounds of cell division known as clonal expansion. This
process is followed by expression of the key transcription factors PPARγ and
C/EBPα and a second, permanent period of growth arrest. Over the course of
terminal differentiation, the preadipocyte converts to a spherical shape,
accumulates lipid droplets, and progressively acquires the morphological
and biochemical characteristics of the mature white adipocyte. The
appearance of PPARγ and C/EBPα activate and/or enhance expression of
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most or all of the genes that characterize the adipocyte phenotype, including
glycerophosphate dehydrogenase, fatty acid synthase, acetyl CoA carboxylase,
malic enzyme, Glut4, insulin receptor, and aP2 or FABP4 (Spiegelman et al.,
1993). At the molecular level, differentiation can be considered as a shift in
gene expression patterns from that of a proliferative, multipotent state to
that which defines the phenotypic appearance of the differentiated stage. In
this sense, changes in transcription factor expression and activity define the
process of differentiation.
It is now well-accepted that the transcriptional network of
adipogenesis involves a sequential activation of C/EBP factors and PPARg
(FIGURE 1.4). First, C/EBPb and C/EBPd mRNA and protein levels rise early
and transiently (Cao et al., 1991; Yeh et al., 1995) and induce the expression
of PPARg through direct transcriptional effects (Fajas et al., 1997; Wu et al.,
1996; Zhu et al., 1995). PPARg is responsible for inducing C/EBPa, which
further reinforces PPARg expression during the differentiation cascade
(Kubota et al., 1999; Rosen et al., 1999; Wu et al., 1999). This positive
feedback feature ensures that the cascade, once initiated, will maintain the
expression of these critical factors as well as the terminal differentiated state.
How PPARg and C/EBPa orchestrate their transcriptional activities remains
uncertain, although it is known that PPARg is sufficient to stimulate most, but
not all, adipocyte markers (Wu et al., 1999) and that PPARg and C/EBPa act
synergistically at many adipogenesis-linked loci (El-Jack et al., 1999;
Lefterova et al., 2008).
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FIGURE 1.4 Transcriptional Regulation of Adipogenesis. The
expression of Pparg is regulated by several pro-adipogenic (green) and
anti-adipogenic (orange) factors. PPARg itself is activated by an as-yetuncharacterized ligand. CCAAT-enhancer-binding protein a (C/EBPa) is
regulated through a series of inhibitory protein–protein
interactions. Figure adopted from Adipocyte differentiation from the inside
out (Rosen and MacDougald, 2006).

1.13 Adipose Tissue Development in vivo
Histological and microscopic observations performed on human and
porcine embryos indicate that white adipose tissue forms early in life.
Developmental history of adipose tissue starts with the sites of fat deposition
in the embryo called the primitive organs of the white adipose tissue (Han et
al., 2011; Wassermann, 2010). The primitive organs are characterized by a
network of capillaries and cells with the appearance of fibroblasts except for
the presence of small fat droplets in cytoplasmic vacuoles (Wassermann,
2010).
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In humans, lipid-filled adipocyte precursors are first visible around
gestational week 14 in structures called fat lobules (Poissonnet et al., 1984).
These primitive adipose tissue depots progressively increase in both size and
number until gestational week 23, when fat lobule number begins to plateau.
In the following weeks, fat lobule growth is almost exclusively accomplished
through hypertrophy of existing adipocytes (Poissonnet et al., 1983;
Poissonnet et al., 1984). In mice, the appearance of cells expressing
adipogenic markers in subcutaneous compartments is observed relatively
late in embryogenesis, with overt lipid filling of white adipocytes being
initiated at birth (Birsoy et al., 2011). Visceral adipose depots form after
birth during the first week of life (Han et al., 2011). Studies in rats show
increases in both adipocyte number and size early in life, followed by a
plateau in adipocyte number by 3 months of age, with WAT mass increasing
thereafter resulting from increased adipocyte size (Greenwood and Hirsch,
1974; Hirsch and Han, 1969). A recent study using inducible, irreversible
labeling of mature adipocytes via the adiponectin promoter (termed
AdipoChaser mice) supports these findings (Wang et al., 2013b).
The developmental origin of adipose tissue in different depots has not
been characterized, with the exception of depots in the head region, which
have been shown to derive from the neural crest (Billon et al., 2007). It is
generally considered that adipocytes are of mesenchymal origin based on the
ability of mesenchymal cells and fibroblastic cell lines to form adipocytes in
culture (Rosen and MacDougald, 2006; Taylor and Jones, 1979). Further,
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recent studies using transgenic mouse reporter showed that mesenchymal
cells expressing pref-1 form early precursors of adipocytes in vivo (Hudak et
al., 2014). Other studies have suggested that white adipocytes are derived
from endothelial (Tran et al., 2012) or hematopoietic lineage (Crossno et al.,
2006; Sera et al., 2009). However, conflicting results of these studies indicate
that the appearance of endothelial lineage markers in mature adipocytes was
due to proximity of adipocytes and vascular structures (Berry et al., 2014;
Berry and Rodeheffer, 2013b), and that hematopoietic linage likely
originated from contamination of macrophages (Berry and Rodeheffer,
2013b; Koh et al., 2007; Tchoukalova et al., 2012). Lastly, based on the
observation that differentiating preadipocytes reside within vascular
compartments of adipose tissue, it was proposed that a subset of pericytes
are adipocyte precursors (Cinti et al., 1984). Lineage tracing using pericyte
marker PdgfRβ-cre:R26R-LacZ mice showed that all mature adipocytes stain
positive for β-galactosidase, and PdgfRβ-expressing cells can form adipocytes
when transplanted into mice (Tang et al., 2008). Developmental origin of
adipocytes may reflect the interplay between vascular growth and
adipogenesis in vivo (Fukumura et al., 2003; Rupnick et al., 2002).
Several studies have isolated different cell subpopulations from total
stroma vascular fraction (SVF) of adipose tissue in an effort to identify
adipocyte precursors. Using flow cytometry and fluorescence-activated cell
sorting (FACS), several recent studies were able to isolate populations of live
adipocyte progenitors with adipogenic properties ex vivo in culture and
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FIGURE 1.5 Model of in vivo adipogenesis. A schematic representation
of the adipocyte cellular lineage is shown. The defined lineage, cell
surface, and transcriptional markers for each cell type are shown below
each listed cell type. Figure adopted from Weighing in on Adipocyte
Precursor (Berry et al., 2014).

in vivo following transplantation (Lee et al., 2012; Rodeheffer et al., 2008;
Tang et al., 2008). This leads to the identification of a population
characterized by the cell surface marker profile
CD45−;CD31−;Ter119−;CD29+;CD34+;Sca-1+;CD24+ (hereafter CD24+),
which is highly adipogenic in culture and capable of considerable expansion
prior to differentiation, leading to reconstitution of an entire functional
adipose depot with correction of hyperglycemia and hyperinsulinemia when
transplanted into lipodystrophic AZIP mice (Rodeheffer et al., 2008). Further
analysis revealed that the CD24+ adipocyte progenitor loses CD24
expression to commit into CD24− preadipocytes, which express early
adipogenic factors PPARg and C/EBPa but not AdipoQ or Perilipin (FIGURE
1.5). Interestingly, adipogenic capacity of CD24+ progenitors is dependent of
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adipose tissue microenvironment (Berry and Rodeheffer, 2013b), suggesting
certain non-adipocyte autonomous factors contribution to regulation of
adipogenesis in vivo. Chapter 6 of this thesis describes a novel blastocyst
complementation technique to elucidate cell-autonomous versus non-cellautonomous mechanisms that participates in regulation of whole body
metabolism and adiposity.

1.14 Disease of Adipogenesis: Lipodystrophy
While the disproportional gain of fat mass is described by obesity,
disproportional loss of adipose tissue is termed lipodystrophy.
Lipodystrophy is a heterogeneous acquired or inherited disorder
characterized by the partial or general loss of adipose tissue (Prieur et al.,
2014). Based on linkage analysis of candidate gene screening, the molecular
basis of lipodystrophy primarily involves genes that regulates adipocyte
differentiation, nutrient uptake (particular fatty acid), and/or lipid droplet
(its main component triacylglycerol) formation (Huang-Doran et al., 2010).
The genetic forms of lipodystrophy are very rare, and a large number of
patients carry no mutations in known genes. In contrast, the most common
form of lipodystrophy is induced by protease inhibitors used to treat HIV,
affecting up to 50 % of HIV patients (Asterholm et al., 2007).
Loss of adiposity results in decreased adipokine secretion,
particularly leptin, and excess lipid deposit in other tissues such as the liver
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with the development of a severe metabolic syndrome, including insulin
resistance, hyperglycemia, and dyslipidaemia in both humans and mouse
models (Reue and Phan, 2006; Savage, 2009; Schott et al., 2004). Despite
their opposite phenotypic appearance in adiposity, obesity and
lipodystrophy syndrome share paradoxical similarity in these metabolic
complications, suggesting common factors on the pathogenesis of these
diseases (TABLE 1.1). In turn, the “lipid overflow” hypothesis proposes that,
since the capacity of adipose tissue to accommodate excess energy in the
form of triglyceride is finite, excessive lipid load, typically in obesity, leads to
ectopic lipid accumulation and insulin resistance (Unger, 2003). Insulin
resistance as a result of such “lipotoxicity” is most prominent in the liver,
skeletal muscles, and pancreas (Huang-Doran et al., 2010). Lipodystrophy is
an extreme example of reduced adipose tissue “capacity” and therefore is
characterised by severe ectopic lipid accumulation and insulin resistance
(Savage, 2009). Moreover, abnormal secretion of adipokines and hormones

TABLE 1.1 Phenotypic Comparisons among Lipodystrophy, Obesity, and
Leptin-Deficiency.
Lipodystrophy

Obesity

Ob/Ob

Fat mass

↓

↑

↑

Leptin

↓

↑

↓

Adiponectin

↓

↓

↓

Inflammatory cytokines

↑↓

↑

↑

Metabolic complications

↑

↑

↑
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from dysfunctional adipose tissue can lead to an altered energy balance and
loss of dynamic metabolic regulation (Asterholm et al., 2007). Consistently,
leptin replacement therapy improves both insulin sensitivity and lipid
metabolism in patients and mouse models with generalized lipodystrophy
(Colombo et al., 2002; Ebihara et al., 2007; Gavrilova et al., 2000; Javor et al.,
2005).
Several mouse models of lipodystrophy have been constructed. These
models not only contribute to understanding disease etiology, but also to
providing different perspectives on the study of normal adipose tissue
physiology. The induced lipodystrophy mouse model FAT-ATTAC (Pajvani et
al., 2005) make it possible to characterize the physiological functions of
adipocytes and their secreted factors by acute fat loss without the
confounding effects of long-term ectopic lipid accumulation in liver and
muscles. Earlier constitutive loss of adipocytes during development,
including PPARg2-knockout mice, flp mice with lipin mutation, and AZIP-F1
(Barroso et al., 1999; Moitra et al., 1998; Peterfy et al., 2001; Zhang et al.,
2004), can be achieved by blocking adipogenesis. These animals seem to
have much more profound consequences on systemic energy homeostasis
compared to a late onset loss, suggesting the important role that adipose
tissue plays during the early developmental stages. More refined time
courses of fat loss during development are needed to understand the effects
of adipose tissue on the developmental aspect of metabolic regulation. In
addition, the ability to precisely block adipogenesis in utero or in the early
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postnatal period will be useful in understanding adipogenesis in vivo. The
blastocyst complementation technique described in Chapter 6 of this thesis
presents a novel genetic approach to study adipogenesis in vivo.
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CHAPTER 2: METHODS AND MATERIALS
2.1 BAC Modificaiton
Recombineering was performed as previously described (Gong et al.,
2003) on a leptin gene containing BAC (RP24-69D4) and with primer
sequence included in supplementary to produce the -22kb to +18kb and 22kb to +8.8kb leptin-luciferase reporter construct and the subsequent
modified construct with 32 bp deletion. Sequences of cloning primers are
included in TABLE 2.1. Genomic sequence and coordinates were based on
NCBI37/mm9 mouse genome. Modified BAC were purified using CsCl
gradient followed by restriction digestion using NotI (NEB) to remove the
cloning backbone. Linearized BAC was separated by gel purification, followed
by electro-elution and spot dialysis to remove debris and contaminants that
might impede embryo manipulation.

2.2 Animal Experiments
Generation of transgenic mice: Leptin-luciferase reporter BACs were
used to generate transgenic animals in either C57BL/6J or FVB N/J mice
(Jackson Lab) using common pronuclear injection techniques (Birsoy et al.,
2008a; Nagy, 2003).
Generation of chimeric mice: AZIP(FVB) chimeras were generated by
injecting CAG-driven tubulin-YFP-ES-cells (B6-Tyrc; Gene Targeting Resource
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TABLE 2.1 BAC Modification Primers.

32bp GalK primer Rev

5’CCTGTCTGAAATGCTGGTCCATGGAGACTTGTTCCCGGG
TGAGGTTCCACCTGTTGACAATTAATCATCGGCA
5’TGTTTTTTGAAATGTATTTAAATATTTATTTATTTTATGT
ATATGAGTATCAGCACTGTCCTGCTCCTT
5’CCTGTCTGAAATGCTGGTCCATGGAGACTTGTTCCCGGG
TGAGGTTCCATACTCATATACATAAAATAAATAAATATTT
AAATACATTTCAAAAAACA
5’TGTTTTTTGAAATGTATTTAAATATTTATTTATTTTATGT
ATATGAGTATGGAACCTCACCCGGGAACAAGTCTCCATGG
ACCAGCATTTCAGACAGG
5’TGCTGGAGACCCCTGTGTCGGTTCCTGTGGCTTTGGTCC
TATCTGTCTTATGTTCAACCTGTTGACAATTAATCATCGGC
A
5’CGGTACCCAATCAATGGTCATGGCTTTCTACGATGTTTG
AGTGTCTACAGACATCTCTCAGCACTGTCCTGCTCCTT
5’TGCTGGAGACCCCTGTGTCGGTTCCTGTGGCTTTGGTCC
TATCTGTCTTATGTTCAAGAGATGTCTGTAGACACTCAAA
CATCGTAGAAAGCCATGACCATTGATTGGGTACCG
5’CGGTACCCAATCAATGGTCATGGCTTTCTACGATGTTTG
AGTGTCTACAGACATCTCTTGAACATAAGACAGATAGGAC
CAAAGCCACAGGAACCGACACAGGGGTCTCCAGCA
5’AGGTTAATCTTTGAAGTCCCTAAAGATTTGAACTTTCCG
CAGAATTGGCTGCAGCGTCCCTGTTGACAATTAATCATCG
GCA
5’TGGTGGCTTCCTGCTGTGGCCTCTTCTTCCCTCCCCTCCC
CAGCACAGCTTCTTGCTTTCAGCACTGTCCTGCTCCTT

32bp 5' deletion oligo

5’AGGTTAATCTTTGAAGTCCCTAAAGATTTGAACTTTCCG
CAGAATTGGCTGCAGCGTCAAGCAAGAAGCTGTGCTGGG
GAGGGGAGGGAAGAAGAGGCCACAGCAGGAAGCCACCA

32bp 3' deletion oligo

5’TGGTGGCTTCCTGCTGTGGCCTCTTCTTCCCTCCCCTCCC
CAGCACAGCTTCTTGCTTGACGCTGCAGCCAATTCTGCGG
AAAGTTCAAATCTTTAGGGACTTCAAAGATTAACCT

32bp deletion sequencing
primer For

5’-AGTTGACCTGTGCTTCCATACCCT

32bp deletion sequencing
primer Rev

5’-TGTTCTCTTATATCCGCCCTGGGT

4bp mutation oligo For

5’TAAAGATTTGAACTTTCCGCAGAATTGGCTGCAGCGTCT
AGTGGGTTAGAGTCTAAcgtaAGTAGAGCAGAAGCAAGAA
GCTGTGCTGGGGAGGGGAGGGAAGAAGAGGCCACAGC

1bp mutation oligo For

5’TAAAGATTTGAACTTTCCGCAGAATTGGCTGCAGCGTCT
AGTGGGTTAGAGTCTAATTcGAGTAGAGCAGAAGCAAGA
AGCTGTGCTGGGGAGGGGAGGGAAGAAGAGGCCACAGC

150kb kb GalK primer
For
22kb GalK primer Rev

150-22kb 5' deletion oligo

150-22kb 3' deletion oligo

8.8kb GalK primer For
18kb GalK primer Rev

8.8-18kb 5' deletion oligo

8.8-18kb 3' deletion oligo

32bp GalK primer For

Center at Rockefeller) into 3.5-day blastocysts from breeding of wild-type
FVB females (Jackson) to AZIP(FVB) transgenic males (Moitra et al., 1998).
Since both the blastocyst and the ES-cells have white coat color, AZIP(FVB)
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chimeras are completely albino. Degree of chimerism was determined by the
percent of YFP-genotype cells in blood DNA samples. AZIP(B6) chimeras
were generated by injection B6-Tyrc ES-cells into 3.5-day blastocysts from
breeding of wild-type C57BL/6J females to AZIP(B6) transgenic males.
AZIP(B6) transgenic mice were generated by backcrossing AZIP(FVB) male
to wild-type C57BL/6J females for more than 7 generations. Chimerism of
AZIP(B6) chimeras were scored by coat color and averaged from two
independent observers as well as quantifying the percentage of Tyrc allele
versus Tyr wild-type allel using Taqman qPCR (Applied Biosystem). AZIP
transgenic mice are genotyped according to previous protocol (Moitra et al.,
1998). Primer sequences are detailed in TABLE 2.2.
TABLE 2.2 Genotype and ChIP primers
CRE For

5'-CAC GAC CAA GTG ACA GCA AT

CRE Rev

5'-AGA GAC GGA AAT CCA TCG CT

gLUC For

5'-GTT GTT CCA TTC CAT CAC GG

gLUC Rev

5'-TCC TCT GAC ACA TAA TTC GCC

gAZIP For

5'-CTG TGC TGC AGA CCA CCA TGG

gAZIP Rev

5'-CCG CGA GGT CGT CCA GCC TCA

gNFYAf_For
gNFYAf_Rev1

5'-GTA AGT CAG GCT CCA GGG
5'-AGG CAA GGC AGA TTT AGG AAG
GTC

gNFYAf_Rev2

5'-GGG TTG TCA GGA TGT TCG CAG

YFP_For

5'-GCG AGG GCG ATG CCA CCT AC

YFP_Rev

5'-GCG AAG CAC TGC AGG GCG TA

FABP4_For

5'-AAT GTC AGG CAT CTG GGA AC

FABP4_Rev

5'-GAC AAA GGC AGA AAT GCA CA

chip_leptin5e_For

5'-CGC AGA ATT GGC TGC AGC GT

chip_leptin5e_Rev

5'-GGT GGC TTC CTG CTG TGG CC

chip_ins_For

5'-GGA CCC ACA AGT GGA ACA AC

chip_ins_Rev

5'-GTG CAG CAC TGA TCC ACA AT
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Housing condition for AZIP mice: Due to cold sensitivity of neonates,
breeding pairs consist of AZIP male and wild-type females are housed in nonventilated cages and in elevated temperature (27˚C-30˚C). AZIP-pups were
weaned around 4 weeks old, upon which the animals are transferred to
standard housing condition.
In vivo Luciferase imaging: Measurement of luciferase reporter
activity in Leptin-BAC transgenic mice was performed with Xenogen IVIS
Lumina imaging system (Caliper), 10 mins after ip-injecting 150mg/kg of
luciferin (PerkinElmer) in 150uL 1XDPBS prepared freshly.
Generation and experiments of adipocyte-specific knockout NF-YA:
Adiponectin-CRE mice were purchased and genotyped according to standard
protocol (Jackson Lab). NFYA-fl/fl strain and its genotyping were described
previously (Bhattacharya et al., 2003). NFYA-fl/fl mice were backcrossed to
C57BL/6J background for at least 8 generations prior to all experiments.
Leptin at 350ng/hour (Amgen) or PBS was delivered for 14 days by
subcutaneously implanted pre-equlibrated osmotic pumps, model 2002
(Alzet). Insulin (Alpco), serum Leptin (R&D Systems), and serum total
Adiponectin (Alpco) were measured by ELISA according to the
manufacturers' protocols using serum samples collected by retro-orbital
bleeding using EDTA coated capillaries (Drummond). Blood glucose was
measured by tail vein sampling using a Breeze2 glucometer (Bayer). High fat
diet treatments used 58Y1 60 kcal% fat (TestDiet). Body adiposity was
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measured by DEXA scan using Lunar PIXImus2 Densitometer and analyzed
with manufacture software (GE Medical Systems). Glucose tolerance test
(GTT) was performed by IP injecting 10% glucose aqueous solution
calculated to 1mg/g of body weight following a 12 to 16 hour overnight fast.
For triglyceride quantification in liver, fresh liver tissue with known weight
(between 60 to 80mg) was homogenized using Polytron in 5%NP-40/water
on ice, followed the assay protocol outlined in Triglyceride Quantification Kit
(Abcam).
Metabolic profiling: Energy expenditure and oxygen consumption
were measured using Oxymax Comprehensive Lab Animals Monitoring
System (Columbus Instrument). Core body temperature was measured using
IPTT-300 transponder probes and DAS-8001Console reader (Bio Medics
Data Systems). The probes were implanted into the peritoneal space.
All animal surgeries were performed under Isothesia (Henry Schein)
delivered via a flow regulator. All animal experiments were performed
incompliance with regulation and approved by institutional board at The
Rockefeller University.

2.3 Biochemical Assays
In vitro Luciferase assay: Various tissues (spleen, muscle, stomach,
brain, heart, liver, kidney, intestine, inguinal adipose tissue, epididymal

44

adipose tissue) were dissected and collected from transgenic mice and flashfrozen with liquid nitrogen. The tissues are homogenized in cell lysis buffer
(Promega) with a polytron homogenizer. Luciferase activity in tissue lysate
was measured using the Luciferase Assay kit (Promega) and normalized to
protein content with a BCA kit (Pierce).
Western Blot: White adipose tissue and liver tissue were collected and
minced with razor blade and heated in 95C in loading buffer for 5min.
Antibodies against NF-YA H209 (Santa Cruz) and b-Actin 13E5 HRP
conjugated (Cell signaling) were used.

2.4 Molecular Experiments
EMSA and supershift assays: EMSA was performed by incubating 6 µg
of adipose tissue nuclear extracts from 12-16 weeks old Lep ob/ob mice
(Jackson Lab) in a 20 µl reaction volume with 10 mM HEPES pH 7.9, 4%
glycerol, 80 mM KCl, 1 mM MgCl2, 2 µg poly (dI-dC), 3 µg BSA, with 20,000
cpm of the 32P-labeled DNA probe for 20 min at room temperature. Samples
were then loaded onto a 4-6% polyacrylamide gel, run at 150V for 4 hours,
dried, detected overnight in a phosphor screen (GE healthcare) and read in
an Amersham Biosciences Typhoon 9400 imager. For supershift assays 2 µg
antibody was added after 20 min of incubation with the probe and incubated
another 20 min before loaded onto the gel. Antibodies were NFY-A (H209),
NFY-B (FL207), C/EBPα (14AA), C/EBPβ (Δ198) from Santa Cruz
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Biotechnology, Inc. The sequence of the wild type 32 bp probe is
TAGTGGGTTAGAGTCTAATTGGAGTAGAGCAG (individual sequences of
mutated oligos are shown in TABLE 2.3).
CHIP assay and luciferase reporter assay: Adipose tissues were
harvested from 8 to 10 weeks old C57BL/6J male mice of either wild-type or
Lep ob/ob genotype (Jackson Lab). Tissues were washed in cold 1XPBS and
minced with razor blade on ice, followed by cross linking in 1%
formaldehyde/PBS for 20min and quenching with glycine for 5min at room
temperature. The tissues were washed with 1XPBS three times and flashfreezed in liquid nitrogen. Frozen cross linked tissues were thawed in buffer
A (20mM Tris, pH7.9, 25% glycerol, 0.1mM EDTA, 0.5% TX-100, 0.5% NP40,
0.5mM PMSF) and homogenized with a douncer on ice. The lysate was span
at 2000xg for 5min to collect the nuclei, which were suspended in CHIP
buffer (50mM HEPES/KOH, pH7.5, 140mM NaCl, 0.1% Na-deoxycholate, 1%
TX-100, 1mM EDTA, 0.1% SDS) with complete protease inhibitor cocktail
(Roche). The nuclei were sonicated at 50% amplitude for 15min on ice. The
1mL of supernatant was used to perform one IP reaction using ProteinG
Dynal beads (Invitrogen), preincubated with 2ug antibody against NF-YA
(H209; Santa Cruz) for 2 hrs. After overnight incubation at 4C on a rotator,
the reaction was washed with high salt buffer (20mM Tris pH8.1, 500mM
NaCl, 2mM EDTA, 1% TX-100, 0.1% SDS) three times and EB buffer once.
Reverse cross link was performed using TE with 1% SDS at 65C for 15min on
a thermomixer. Sample was treated with RNase and protrease K (Sigma),
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TABLE 2.3 Gel shift and super shift assay oligonucleotides.
32bp wt F
32bp wt R
32bp mut1F
32bp mut2R
32bp mut2F
32bp mut2R
32bp mut3F
32bp mut3R
32bp mut4F
32bp mut4R
32bp mut5F
32bp mut5R
32bp mut6F
32bp mut6R
32bp mut7F
32bp mut7R
32bp mut8F
32bp mut8R
32bp mut9F
32bp mut9R
32bp mut10F
32bp mut10R

TAGTGGGTTAGAGTCTAATTGGAGTAGAGCAG
CTGCTCTACTCCAATTAGACTCTAACCCACTA
TAGTGGGTTAGAGTCcAATTGGAGTAGAG
CTGCTCTACTCCAATTgGACTCTAACCCA
TAGTGGGTTAGAGTCTcATTGGAGTAGAG
CTGCTCTACTCCAATgAGACTCTAACCCA
TAGTGGGTTAGAGTCTAcTTGGAGTAGAG
CTGCTCTACTCCAAgTAGACTCTAACCCA
TAGTGGGTTAGAGTCTAAcTGGAGTAGAG
CTGCTCTACTCCAgTTAGACTCTAACCCA
TAGTGGGTTAGAGTCTAATcGGAGTAGAG
CTGCTCTACTCCgATTAGACTCTAACCCA
TAGTGGGTTAGAGTCTAATTcGAGTAGAG
CTGCTCTACTCgAATTAGACTCTAACCCA
TAGTGGGTTAGAGTCTAATTGcAGTAGAG
CTGCTCTACTgCAATTAGACTCTAACCCA
TAGTGGGTTAGAGTCTAATTGGcGTAGAG
CTGCTCTACgCCAATTAGACTCTAACCCA
TAGTGGGTTAGAGTCTAATTGGAcTAGAG
CTGCTCTAgTCCAATTAGACTCTAACCCA
TAGTGGGTTAGAGTCTAATTGGAGcAGAG
CTGCTCTgCTCCAATTAGACTCTAACCCA

purified with PCR purification kit (Qiagen), and analyzed with qPCR (see
supplementary for primer sequences). For Luciferase reporter assay, 115bp
leptin enhancer site (GAGAACACTTAACAGCAAAGGTTAATCTTTGAAGTCCCT
AAAGATTTGAACTTTCCGCAGAATTGGCTGCAGCGTCTAGTGGGTTAGAGTCTA
ATTGGAGTAGAGCAGAAGCAAG) was PCR amplified using -22kb to +8.8kb
leptin BAC as template and primers 5’-gcggcgcg CTCGAG AAC ACT TAA CAG
CAA AGG TTA ATC and 5’-cgcccggc AGATCT CTT GCT TCT GCT CTA CTC CAA
TTA GA. The PCR product was cloned into pGL4.15 (Promega) between XhoI
and BglII sites. Expression plasmids of NF-YA, NF-YB, NF-YC, and CEBPa in
pCMV-SPORT6 vector as well as vector plasmid were commercially available
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(Open Biosystem). The constructs were transfected into 293T cells using
Lipofectamine 2000 (Invitrogen). The assay was performed using Duo
Luciferase Reporter Assay System (Promega).
Gene expression analysis: To extract RNA from adipose tissues,
approximately 70mg of adipose tissue was harvested and flash-frozen in
liquid nitrogen. The frozen tissue was homogenized with a Polytron
homogenizer for 30 sec in 700uL of Trizol Reagent (Invitrogen) on ice. After
removing debris with centrifugation, the lysate was added to a column of
Direct-zol RNA MiniPrep (Zymo) and processed according to the
manufacture’s manual. cDNA was synthesized using qScript cDNA SuperMix
(Quanta Bioscience). Quantitative PCR was done using Quantitect SYBR Green PCR
Kit (Qiagen) and 7500 Fast Real-Time PCR (Applied Biosystem) with primers
specific for each gene of interest (TABLE 2.4).

2.5 Tissue Culture Experiments
Gene knockdown and differentiation in 3T3-L1: Knockdown
of NFYA in 3T3-L1 cells was achieved by lentiviral vector-mediated shRNA
expression with MISSION shRNA plasmids 439 (CCGGAGCAAGTTACAGTCC
CTGTTTCTCGAGAAACAGGGACTGTAACTTGCTTTTTTG) and 441 (CCGGCCA
AACCAAGCTGACGAAGAACTCGAGTTCTTCGTCAGCTTGGTTTGGTTTTTG)
(Sigma). Lentivirus was generated in 293T cells using 2nd generation
packaging system (Addgene) and Lipofectamine 2000 (Invitrogen). Viral
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TABLE 2.4 qPCR primers for gene expression analysis
Gene
NFYA
HPRT1
AdipoQ
Leptin
Adipsin
Resistin
TNFa
FABP4
PPARg
CEBPa
CEBPd
CD36
Glut4
Ehhadh
Hadha

Forward
5’-ATC AAC AGG CCA ACC CAT CA
5’-TCA GTC AAC GGG GGA CAT
AAA
5’-GCC GTG ATG GCA GAG ATG
GCA C
5’-GCA AGA AGA AGA AGA TCC
CAG G
5’-CAT GCT CGG CCC TAC ATG G
5’-AAG AAC CTT TCA TTT CCC CTC
CT
5’-TCC CAG GTT CTC TTC AAG GGA
5’-AAG GTG AAG AGC ATC ATA
ACC CT
5’-GCA TGG TGC CTT CGC TGA
5’-CAA GAA CAG CAA CGA GTA
CCG
5’-CGA CTT CAG CGC CTA CAT TGA
5’-ATG GGC TGT GAT CGG AAC TG
5’-GTG ACT GGA ACA CTG GTC
CTA
5’-ATG GCT GAG TAT CTG AGG
CTG
5’-ACT ACA TCA AAA TGG GCT
CTC AG

PGC1a
UCP1
Pref1

5’-GAA GAA GAC TCA CCA GAA
GCA G
5’-GAT GCG CTC TCG TTC AAG AT
5’-GCT TTG CCT CAC TCA GGA TT
5’-AGT GCG AAA CCT GGG TGT C

Klf4

5’-ACA CCT GCG AAC TCA CAC AG

Ctsk

Reverse
5’-CTG GAT CTG TCC AGG AGG CA
5’-GGG GCT GTA CTG CTT AAC
CAG
5’-GGA AGC CCC GTG GCC CTT
CAG
5’-CAG ATA GGA CCA AAG CCA
CAG
5’-CAC AGA GTC GTC ATC CGT CAC
5’-GTC CAG CAA TTT AAG CCA
ATG TT
5’-GGT GAG GAG CAC GTA GTC GG
5’-TCA CGC CTT TCA TAA CAC ATT
CC
5’-TGG CAT CTC TGT GTC AAC CAT
G
5’-GTC ACT GGT CAA CTC CAG CAC
5’-CTA GCG ACA GAC CCC ACA C
5’-GTC TTC CCA ATA AGC ATG TCT
CC
5’-CCA GCC ACG TTG CAT TGT AG
5’-GGT CCA AAC TAG CTT TCT GGA
G
5’-AGC AGA AAT GGA ATG CGG
ACC
5’-TCC AGG TTA TGG GCA GAG
ATT
5’-GGT GTC TGT AGT GGC TTG AT
5’-TAA GCC GGC TGA GAT CTT GT
5’-GCC TCC TTG TTG AAA GTG GTC
A
5’-ACT TCT GGC ACT GAA AGG GC

supernatants were supplemented with 8 μg/ml polybrene and added to cells
for infections for 36 hours. Cells were selected with 3 μg/ml puromycin
(Sigma) for 48 hours, expanded and seeded for differentiation experiments.
3T3-L1 cells were maintained in DMEM with 10% heat inactivated NCS
(Invitrogen) in 5% CO2. Differentiation was performed as previously
described (Zebisch et al., 2012). Oil red staining was performed as previously
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described (Zebisch et al., 2012). Non-differentiated controls were maintained
in DMEM with 10% FBS. RNA extraction was performed using RNeasy
(Qiagen) following manufacturer’s instruction.

2.6 Statistical Analysis
Two-ended, unpaired Student T’s test was used. Error bars indicated
standard error of mean. Unless specifically mentioned, * indicated p<0.05, **
indicated p<0.01, *** indicated p<0.001, and **** indicated p<0.0001.
Outliers were detected by comparing to corresponding Thomspon Tau values.
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CHAPTER 3: TRANSCRIPTIONAL REGULATION OF LEPTIN BY
DISTAL ELEMENTS
3.1 Introduction
Leptin is an adipocyte hormone that functions as the afferent signal in
a negative feedback loop that maintains homeostatic control of adipose
tissue mass. When weight is lost, leptin level falls thus stimulating appetite
and altering metabolism and neuroendocrine function leading to weight gain
(Coll et al., 2007). Conversely, in leptin responsive individuals, weight gain
results in an increase in leptin levels and a reduction of food intake and body
weight (Friedman-Einat et al., 2003; Jequier, 2002). Leptin production by
adipocytes is highly correlated to body adiposity (Frederich et al., 1995;
Maffei et al., 1995b) and is capable of exerting profound effects on both
energy intake and energy expenditure (FIGURE 3.1). A fuller understanding
of the elements of this system could have important implications for the
pathophysiology and treatment of obesity.
Particularly, the changes in plasma leptin levels are associated with
changes in leptin mRNA per adipocyte, and the levels of leptin mRNA per cell
are highly correlated with intracellular lipid content (Couillard et al., 2000;
Maffei et al., 1995b; Marikovsky et al., 2002; Motyl and Rosen, 2012). These
observations have raised the possibility that the regulatory elements of the
leptin gene consist of a putative lipid sensing mechanism that regulates leptin
expression in response to changes in the amount of intracellular lipid and
adipocyte size. However, the nature of such a mechanism is not known. To
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FIGURE 3.1 Plasma Leptin is Highly Correlated with body adiposity.
In leptin responsive individuals, weight gain results in an increase in
leptin levels and a reduction of food intake and body weight. By this
mechanism, body weight is maintained within a relatively narrow range.
Plasma leptin thus serves as a surrogate for fat mass. The changes in
plasma leptin levels are associated with changes in leptin mRNA per
adipocyte and the levels of leptin mRNA per cell are highly correlated with
intracellular lipid content.

elucidate this, we undertook a similar approach to that used to identify a
cholesterol sensing pathway. In Brown and Goldstein’s seminal work on the
regulation of cholesterol metabolism, the identification of the sterol response
element (SRE), a key cis-element, led to the identification of SREBP (SRE
binding protein) and the cholesterol sensor SCAP (SREBP cleavage-activating
protein) that controls a set of cleavages that leads to the transport of this
transcription factor to the nucleus (Brown and Goldstein, 1999; Lee et al.,
1994; Nohturfft et al., 2000). As such, we focus our endeavor on dissecting
the transcriptional regulation of the leptin gene, although there is no
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evidence to exclude other means of gene expression regulation such as posttranscriptional modification.
Analysis of quantitative expression of the leptin gene necessitates that
studies be conducted in vivo because cultured adipocytes express orders of
magnitude lower amounts of leptin mRNA compared to adipcoytes in vivo
(Macdougald et al., 1995; Mandrup et al., 1997). A previous study from our
laboratory showed that a leptin-luciferase BAC reporter construct extending
from from -22kb to +150kb (RP2469D; mm9 chr6: 28987901-29158589)
showed faithful qualitative and quantitative expression in vivo with
increased reporter expression in ob/ob adipocytes and decreased expression
in adipocytes after fasting (Birsoy et al., 2008b). This finding was consistent
with data from another report showing that this BAC and a second clone
extending from -160kb to +18kb (mm9 chr6:28854232-29028379) showed
fat-specific reporter expression, although in the previous report, studies of
reporter expression in ob/ob and fasted mice were not performed (Wrann et
al., 2012). This part of the thesis presents the follow-up study on a series of
modified leptin-luciferase BAC reporter mice to identify cis- and transelements regulating leptin transcription.
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3.2 Results and Discussion
In aggregate of previous leptin-BAC reporter mice, it is inferred that
DNA sequences between -22kb to +18kb (mm9 chr6:28987900- 29199010)
are likely to be sufficient for leptin transcriptional regulation (FIGURE 3.2A).
To test this directly, we generated a BAC-transgenic luciferase reporter
mouse carrying a single 40kb leptin-luciferase BAC that extends from -22kb
to +18kb, the region of overlap between the aforementioned BAC clones
(FIGURE 3.2B). Using the same strategy as in a previous study (Birsoy et al.,
2008b), luciferase was cloned into the leptin start codon in the second exon
of the leptin gene together with a polyadenylation signal (this construct is
used to generate all subsequent constructs presented in this chapter) so that
luciferase is expressed under the control of the leptin promoter.
Two out of two founders expressed luciferase specifically in adipose
tissue as shown using in vivo luciferase imaging and by analyzing luciferase
activity from tissue lysates under chow-fed ad libitum (one representative
animal shown as “fed” in FIGURE 3.2B). In addition, we did not find luciferase
expression in the GI tract, muscle, brain or any other visceral organs in which
low levels of leptin gene expression have previously been reported (Birsoy et
al., 2008b; Rosenbaum et al., 2002). Quantitative regulation of luciferase
expression was assayed by crossing the reporter mice to ob/ob animals,
which increases endogenous leptin expression (Note, the ob mice that were
used carry a mutation of the leptin coding sequence but still show marked
induction of leptin gene expression), and by food restricting wild-type mice
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FIGURE 3.2 Analysis of Leptin-Luciferase BAC-transgenic animals. (A). A
luciferase construct including a poladenylation signal was cloned into the Leptin
initiation codon of two nested leptin-BAC clones by homologous recombination
in bacteria, -156kb to +18kb (RP2433803; chr6:28854232-29028379) and -22kb
to +148kb (RP2469D4; chr6: 28987901-29158589) and both recapitulate leptin
expression in vivo, suggesting that the essential regulatory element of leptin
must be contained in the 40kb region -22kb to +18kb. (B). Transgenic founders
carrying a single clone of -22kb to +18kb leptin-luciferase BAC, the region of
overlap between the two BACS in (A), showed adipose tissue specific luciferase
expression using in vivo imaging (one representative mouse out of 2 founder
mice as “fed”). The level of luciferase with metabolic status where fasting
reduced Luciferase expression by 145.4-folds in eWAT (p=0.09) and 35.6-folds
(p=0.0054) in iWAT and crossing to ob/ob genotype increase expression by 3.3folds in eWAT (p=0.02) and 4.7-folds in iWAT (p=0.0083) (labeled as “fasted”
and “ob/ob” respectively in B). The numbers of animals used are 4 for fasted, 7
for fed, and 4 for ob/ob. Luciferase assays from tissue lysate confirm that
luciferase expression is qualitatively and quantitatively regulated similarly to
leptin.

for 48 hours to lower endogenous leptin expression (representative images
are shown and labeled as “ob/ob” and “fasted” respectively in FIGURE 3.2B).
Luciferase expression was increased 3.3 fold in eWAT, p=0.02, and 4.7-fold in
iWAT, p=0.0083, in ob/ob background (n=4) and decreased 145.4-fold in
eWAT, p=0.094, and 35.6-fold in iWAT, p=0.0054, after fasting(n=4); both
results are compared to 7 animals from transgenic line -22kb to +18kb that
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are fed ab libitum. These data confirmed that all of the cis-elements required
for qualitative and quantitative expression are within this 40 kb interval and
provided a starting point for the identification of cis-elements and transfactors responsible for this regulation.
We then generated a comprehensive set of 5’ and 3’ deletions, the data
from which revealed that there were redundant cis-elements upstream and
downstream of the leptin transcription start site. Thus in order to further
study leptin gene regulation, we needed to subdivide the leptin gene into
separate 5’ and 3’ reporter constructs. A manuscript on the complete series
of leptin-luciferase BAC transgenic mice study is in preparation and partial
data is available in previous thesis work (Birsoy, 2009).
To further study the 5’ cis-element without the complication from 3’
element, we then generated a leptin-luciferase BAC that extends from -22kb
to +8.8kb BAC clone (chr6:28987900- 29019010, ending at exon 2 of the
leptin gene, thus excluding any element 3’ to leptin gene). All of the founders
(5 out of 5) of this new -22kb and +8.8kb leptin-luciferase BAC were found to
express luciferase specifically in vivo. Quantitative regulation of leptin
expression was confirmed by crossing the transgenic animals to ob/ob where
we found a 1.5-fold increase in luciferase in eWAT, p=0.46, and a 3-fold
increase in iWAT, p=0.0013 (n=3 for ob/ob). Fasting resulted in a 17-fold
decrease in eWAT, p=0.019, and 6.5-fold decrease in iWAT, p=0.0002, leptin
expression (n=6 for starved), compared to 8 wild-type ab libitum fed animals
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(FIGURE 3.3A). Individual founders showed similar expression pattern
(FIGURE 3.3B). These data confirm that sequences between -22kb to +8.8kb
can, or in another word the 5’ upstream of leptin is sufficient to, recapitulate
qualitative and quantitative expression of the leptin gene in vivo.
We next performed a homology search of sequences within this 22kb and +8.8kb interval and identified an 115bp sequence (mm9
chr6:28993746-28993860) that is highly conserved among all mammals
including mice (FIGURE 3.4). We found that 84.4% of the 115bp sequence is
identical between human (GRCh37/hg19 genome) and mouse (NCBI37/mm9
genome) and there is 73.9% sequence identity between platypus (WUGSC
5.0.1/ornAna1 genome) and mouse. Gel shift assays using a series of 5
overlapping 32 bp oligonucleotides spanning this 115bp region assays were
performed using nuclear extracts from adipose tissue of ob/ob mice and
other tissues. One of these 32 bp oligonucleotides showed a clear gel shift
activity using nuclear extract prepared from adipose tissue, as well as liver
and spleen (FIGURE 3.5A; data for liver and spleen not shown). This 32 bp
segment included a CCAAT-box on the minus-strand which is known to be a
binding site for a number of transcription factors including the CEBP and the
NF-Y transcription factors. Further, gel shift assays with mutant oligos
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FIGURE 3.3 Analysis on -22kb to +8.8kb leptin-luciferase BACtransgenic animals. (A). A leptin-Luciferase BAC extending from -22kb to
+8.8kb (5 founders) also recapitulates leptin expression in vivo, showing
that the included sequences along are sufficient for leptin regulation.
Schematic maps of the three reporter transgenes are shown over the
respective animals with the yellow bands indicating luciferase, the black
segments indicating exons of leptin, the white segments indicating introns
of leptin, the blue segments indicating genomic sequence framing leptin,
and the red band indicating an internal deletion. All heat maps are scaled
to minimum 0 and maximum 2000 luminescence counts in the
manufacturer’s program. (B). Individual founders of -22kb to +8.8kb, 5
mice, all showed adipose tissue specific leptin expression. Each tissue of
individual transgenic founders (5 mice) of -22kb to +8.8 kb construct is
shown. Luciferase activities are normalized to total protein amount as
measured by BCA assay. Schematic maps of the two reporter transgenes
are shown over the respective panels.
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FIGURE 3.4 Conserved Non-Coding Region Upstream of leptin. The
figure includes an 115bp region at -16.5kb of leptin (mm9
chr6:28993746-28993860) that is highly conserved among all mammals
including mice. We found that 84.4% of the 115bp sequence is identical
between human (GRCh37/hg19 genome) and mouse (NCBI37/mm9
genome). Genome information extracted from UCSC Genome Browser.

showed that base changes within the CCAAT sequence abrogated this DNAprotein interaction (FIGURE 3.5B).
To assess whether it was NF-Y or another DNA binding protein that
was responsible for the activity, the gel shift assays were repeated in the
presence of anti-NFYA (H209, Santa Cruz) and anti-NFYB (FL207, Santa
Cruz). These data revealed a clear super-shift in the presence of the antibody
which is directed against two subunits of the factor, NF-YA and NF-YB
(FIGURE 3.5C). In contrast, antibodies to two other CCAAT-box binding
protein C/EBPA or C/EBPB (14AA and Δ198 respectively, Santa Cruz), both
of which are known to play a role in adipocyte function, did not result in a
super-shift. To confirm that NF-Y binds to the CCAAT sequence of the leptin
gene in vivo, chromatin immunoprecipitation (ChIP) assays from adipose
tissue nuclear extract were performed. The ChIP assay revealed a 2.7-fold
enrichment (p=0.02) of the NF-Y binding sequences from ob/ob inguinal
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FIGURE 3.5 Identification of an NF-YA binding site between -16.401kb to 16.370kb. A series of overlapping radioactive oligonucleotide probes were used
to perform gel shift assay using adipose tissue nuclear extract from ob/ob mice in
this region to identify enhancer site. Two of the five probes showed DNA-binding
activity in (A) and the 5’5 site containing a 32bp sequence from -16.401kb to 16.370kb (mm9 chr6: 28993820- 2899385) was further analyzed. (B). A series
of oligos of the 32 bp sequence of 5’5 site with single mutations (from “wt”
sequence to “mut” in figure) identified a core binding sequence of a DNA binding
protein compatible with NF-Y binding. (C). Super-shift assays shown in were
performed for possible CCAAT binding proteins NF-YA (H209), NF-YB (FL207),
C/EBPa (14AA), or C/EBPb (Δ198) to gel shift reaction with wild-type
oligonucleotide. A super-shift using the NF-YA (H209) and NF-YB (FL207)
antibodies is indicated with an arrow. Antibodies against CEBPs did not cause a
super-shift. (D). CHIP assay in mouse subcutaneous white adipose tissue using
anti NF-YA shows binding at the identified 32bp enhancer sequence (labeled 5’e)
in 10 week old ob/ob mice. Fold enrichment is normalized to insulin (labeled
Ins), a locus that is not expressed in adipose tissue. (E). NF-YA mRNA levels as
normalized against HPRT1 expression are indistinguishable in fast, fed, or ob/ob
adipose tissue. (F). An ex vivo luciferase assay was performed using a luciferase
construct driven by an 115bp region encompassing the 32bp sequence cotransfected with NF-YABC subunits (lane NF-Yabc) showed a 60-fold increase in
luciferase activity compared to vector-only control (VC), while co-expression of
the reporter with CEBPA, or NFYA alone did not increase activity.
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adipose tissue using the anti-NFYA antibody (H209, Santa Cruz) compared to
DNA sequences from the insulin gene (FIGURE 3.5D). Insulin was used as the
control region because the gene is not expressed in adipose tissues. We next
assayed the levels of NF-Y mRNAs and did not find a change in mRNA levels
among ob/ob, and wild-type mice fed ab libitum and fasted (FIGURE 3.5E).
A functional analysis of the transcriptional activity NF-Y was
demonstrated by co-transfecting plasmids expressing three subunits of NFYA, NF-YB, and NF-YC together with a luciferase reporter cloned downstream
of the 115bp homologous sequence of leptin enhancer. We found a 60-fold
increase in luciferase expression when the NF-Y plasmids were cotransfected compared to vector control (FIGURE 3.5F). Consistent with the
super-shift data, expressing C/EBPA failed to increase luciferase expression
in the same assay, nor did NF-YA alone consistent with previous data
showing that all three NF-Y subunits are required for its transcriptional
activity. Together, these experiments showed that NF-Y binds to the CCAATbox 16.5kb upstream of the leptin TSS and can increase the level of
expression of a reporter construct. The identified cis-element is a true
enhancer that can activate transcription independent of their location,
distance or orientation with respect to the promoters of genes (Ong and
Corces, 2011). Note that since NF-Y was identified using a candidate
approach, it is likely that other transcription factors also interact with this
enhancer site. Other trans-elements can be identified using the same in vitro
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luciferase assay combined with cDNA library of transcription factors, which
is an approach under active pursue.
Although the C/EBP family transcription factors are known for
inducing preadipocyte differentiation and in modulating gene expression in
the fully differentiated adipocyte (Darlington et al., 1998), it is not
unexpected that we did not detect bindings of either C/EBPa or C/EBPb at
the identified distal enhancer. As mentioned, leptin is expressed at much
higher levels in vivo versus in vitro such as in differentiated 3T3-L1 or F442
cells (Macdougald et al., 1995; Mandrup et al., 1997). Since these cultured
models express C/EBP factors and their targets in abundance (Soukas et al.,
2001), it can be inferred that adipocyte specific expression of leptin is
controlled by a different set of transcriptional mechanism from that dictating
adipogenesis, at lease in vitro. Nonetheless, since expression of leptin serves
as a hallmark of adipocyte maturation both in vivo and in vitro (Hwang et al.,
1997; Slieker et al., 1998), the in vivo adipogenesis events leading to leptin
activation during development is worth of further investigation.
To confirm a role for the 32 bp sequence that includes the NF-YA
binding site in vivo we generated a -22 kb to +8.8 kb leptin-luciferase BAC
reporter line in which there was an internal deletion of the 32 bp that
included the NFY-A CCAAT-sequence. (GTCTAGTGGGTTAGAGTCTAATTGGA
GTAGAG found between mm9 chr6: 28993820- 2899385; FIGURE 3.6A).
This deletion completely abrogated reporter expression in all 11 transgenic
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FIGURE 3.6 Deletion of a 32bp sequence abolish leptin expression in
vivo. (A) A 32bp sequence internal deletion of the 32 bp NF-YA binding
site (GTCTAGTGGGTTAGAGTCTAATTGGAGTAGAG; mm9 chr6: 2899382028993851) in the -22kb to +8.8kb BAC (11 mice) abrogated Luciferase
expression, confirming that these sequences are essential for leptin
expression in vivo. (B). Luciferase activity of individual tissues from each
founders of the -22kb to +8.8 kb leptin-luciferase gene with the 32 bp
deletion are graphed, showing no adipose tissue specificity nor
comparable expression level to wild-type construct. Luciferase activities
are normalized to total protein amount as measured by BCA assay.
Schematic maps of the two reporter transgenes are shown over the
respective panels.
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founders using in vivo Luciferase imagining as well in biochemical assays
from tissue lysates as described above (FIGURE 3.6B). To confirm that the
reverse CCAAT-box is essential for the transcriptional activity observed from
the -22 kb to +8.8 kb leptin-luciferase BAC reporter line in vivo, we generated
two additional transgenic lines: a 4bp mutation from 5’-ATTGG to 5’-Acgta
(construct NFY-4bp; mm9 chr6: 28993840- 28993843) and a 1bp mutation
to 5’-ATTcG (construct NFY-1bp; mm9 chr6:28993842). For NFY-4bp 5 out
of 5 and for NFY-1bp 4 out of 5 transgenic founders lost leptin expression in
vivo (FIGURE 3.7A and B). These data confirmed that the CCAAT-box element
is essential for leptin and led us to test the function of NF-YA in adipocytes in
vitro and in vivo (see Chapter 4).
This finding is in contrast to data from a prior publication by Wrann et
al suggesting that a DNA sequences between -5.2kb and the proximal
promoter are responsible for leptin expression in vivo (Peterfy et al., 2001).
In this prior report, the authors generated the same -22kb to +18kb Leptin
BAC clone (except for using EGFP as oppose to Luciferase), that we used to
recapitulate Leptin expression. They then used a -5.2kb to +18kb BAC clone
and showed that these sequences can also recapitulate fat specific leptin
expression though quantitative expression in ob/ob and fasted mice was not
analyzed. The authors thus concluded that the regulatory element controlling
fat specific leptin expression must reside within the 5.2kb 5’ region. However,
we have found that there are redundant elements controlling leptin
expression including either the 32 bp sequence on the 5’side at -16.5kb
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FIGURE 3.7 Point mutations at NFY binding site ablate leptin
transcription. Two transgenic lines were generated by pointmutagenesis on -22kb to +8.8kb leptin-luciferase BAC (top diagram). The
red bar corresponds to the sequences in each line and mutated base pairs
are in low case red letters. (A). Four base pair mutation of reverse CCAATbox from ATTGG to Acgta abolishs leptin expression in 5 out of 5 founders.
(B). Single base pair mutation from ATTGG to ATTcG abolishs leptin
expression in 2 out of 2 founders. Biochemical assay from tissue lysate of
individual founders are on the right.

presented here or a 3’ sequences at approximately +14kb (manuscript in
preparation). Either of these 5’ or 3’ sequences is capable of independently
conferring fat specific expression of the leptin gene (manuscript in
preparation). For example, we find that a BAC clone that extends from 16.4kb to +8.8 kb does not lead to fat specific expression of a luciferase
reporter thus excluding sequences between -5.2 kb and +1bp as being
capable of supporting leptin expression. Thus the reason the BAC extending
from -5.2kb to +18kb shows fat specific expression is because of sequences at
~ +14 kb, not sequences between -5.2 kb and the transcription start site. The
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findings explain our data showing that there is faithful qualitative and
quantitative expression of a 5’ reporter extending from -22 kb to +8.8 kb, and
that an internal deletion of a 32 bp sequence at -16.7 kb abrogates this
expression despite the fact that more proximal promoter elements between 5.2 kb to +1bp are intact.
To investigate in vivo function NF-Y binding site, it will be necessary to
generate knockout mouse model. With the recent advance in genome editing
technique using CRISPR (Wang et al., 2013a), precise deletion or mutation of
the sequence of interest can be achieved in one generation. Although the
aforementioned redundancy of multiple cis-elements could mask the
potential effect of knockout, such mouse model will also provide information
on broader role of leptin regulation in vivo that was beyond the scope of
luciferase reporting.
Since NF-Y is ubiquitously present in many tissues, adipocyte specific
and fat mass dependent expression of leptin cannot be explained by the
regulatory function of NF-Y factor alone. Recent advances in understanding
transcriptional mechanism suggested an important role of repressor in
conferring spatial and temporal gene expression (Ong and Corces, 2011).
Since leptin gene is not expressed until late gestation in mice in differentiated
adipocytes, transcription of leptin must be repressed in the early
developmental stages of adipocytes. Indeed, several studies have suggested
that NF-Y is capable of activating as well as inhibitory regulation, either by
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direct interaction with different DNA sequences or by recruiting different cofactors (Peng and Jahroudi, 2002; Zhu et al., 2012). Genome wide study
showed that NF-Y functions as “switch” between proliferation and
differentiation in stem cell by re-directing the transcriptional profile in global
level (Ceribelli et al., 2008; Donati et al., 2008). The precise molecular
mechanism of leptin transcriptional regulation remains to be explored.
Particularly, identification of other cis-elements and corresponding transelement will facilitate further investigation on interactions among these
factors. One straightforward speculation is that other cis-elements are
modulated by some yet unknown adipocyte specific factors, while NF-Y
serves as co-factor in transcriptional activation. Unfortunately, there is a lack
of unbiased method to identify trans-factor to a known sequence, and
classical biochemical purification of transcription factor requires large
amount of material that is impractical to obtain from animal tissue (Yang,
1998).
Recent studies highlight the importance of NF-Y on stem cell
proliferation and maintenance, notably in mesenchymal linages including
myoblast and hematopoetic stem cell (Bungartz et al., 2012; Farina et al.,
1999; Gurtner et al., 2008; Gurtner et al., 2003). Similar to our observation in
3T3-L1 cells where NF-Y expression is reduced during adipogenesis, downregulation of NF-Y accompanies differentiation in both the hematopoetic and
muscle lineage. NFY has also been shown to control tissue specific gene
expression by interacting with other cell specific DNA binding proteins. For
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instance, a study comparing fetal and adult erythrocytes shows that NF-Y
differentially recruits activators or repressors to induce or inhibit the
gamma-globin gene during development (Zhu et al., 2012). Biochemical
studies also showed that NF-Y displays histone-like DNA binding activities,
and can regulate transcription in a non-sequence specific manner (Nardini et
al., 2013; Oldfield et al., 2014). Further studies of NF-Y and other factors will
be required to dissect how NF-Y controls qualitative and quantitative leptin
transcription.
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CHAPTER 4: NF-Y KNOCKOUT AS A NOVEL LIPODYSTROPHY
MODEL
4.1 Introduction
Identification of NF-Y as a trans-element regulating leptin gene
expression, described in Chapter 3, prompted us to study its function in the
3T3-L1 adipogenesis model and in a knockout mouse model. NF-Y (also
known as CBP, CCAAT-box Binding Protein) is a transcription factor
composed of three subunits, NF-YA, NF-YB, and NF-YC (also as CBP-B, CBP-A,
CBP-C respectively). NF-Y recognizes the CCAAT sequence mostly through
the conserved C-terminus of NF-YA, although all three subunits are required
for DNA binding activity (Mantovani, 1999). A germ line knockout of NF-YA is
embryonic lethal at E8.5, demonstrating that NF-Y is essential for early
development (Bhattacharya et al., 2003). In addition, NF-Y is required for
stem cell maintenance and for controlling cell type specificity during
differentiation, particularly in mesenchymal lineages such as blood cells,
myoblasts, and osteoblasts (Bungartz et al., 2012; Goeman et al., 2012;
Gurtner et al., 2003; Zhu et al., 2005). NF-Y has been implicated in human
diseases including myodystrophy, neurodegenerative diseases, cancer, and
cardiovascular diseases (Ly et al., 2013; Tohnai et al., 2014; Yamanaka et al.,
2014). From in vitro studies, NF-Y binds to the promoters of genes
controlling cholesterol and fatty acid synthesis as well as adiponectin
although its function in adipogenesis and tissue specific gene regulation in
vivo has not been evaluated (Park et al., 2004; Reed et al., 2008).
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In Chapter 3, we showed that a 32bp sequence at -16.5kb of the leptin
gene is essential for in vivo expression of leptin in luciferase reporter mice. A
computational analysis identified a CCAAT-box sequence this 32 bp segment
and NF-Y was identified as the binding protein using a candidate approach in
super-shift assay. ChIP using an anti-NFY antibody confirmed that it binds to
this site in vivo. A knockdown of NF-YA in vitro and a fat specific ablation of
NF-YA in vivo both decreased adipogenesis and leptin gene expression, but
the decrease in leptin expression appeared, in part, to be a result of a general
effect on adipocyte development rather than an exclusive effect on the leptin
gene. Thus animals with a knockout of NF-YA develop a moderately severe
lipodystrophy with low leptin levels and a metabolic phenotype that is
remediable with leptin therapy. Overall, these data identify a new etiology for
lipodystrophy and further suggest that there could be a large number of
other causes for this disorder. The data also provide a framework for future
studies aimed at identifying the gene regulatory mechanisms that control
leptin gene expression.
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4.2 Results and Discussion
Preadipocyte culture model 3T3-L1 has been widely used in studies of
adipogenesis. Since 3T3-L1 cells can be induced to differentiate into lipidfilled adipocytes in vitro in the presence of insulin, dexamethasone and IBMX
(FIGURE 4.1A), this model allows precise control over the process of
adipocyte differentiation (Zebisch et al., 2012). In wild-type 3T3-L1 cells, the
mRNA levels of NF-YA were detected early in undifferentiated 3T3-L1 cells
and decreased approximately 10-fold after induction of adipocyte
differentiation by hormone treatment starting from day3 (FIGURE 4.1B). This
pattern is similar to other preadipocyte genes such as KLF4 and Pref-1
(FIGURE 4.1C). In contrary, adipogenic transcription factors PPARg and
C/EBPa as well as mature adipocyte markers show increase expression
following differentiation (FIGURE 4.1D and E).
To assay a role for NF-Y in adipogenesis, we next introduced RNAi
constructs, labeled 439 and 441, targeting NF-YA into 3T3L1 cells using
lentivirus. We first confirmed that NF-YA down-regulation is an adipogenesis
specific effect, because un-differentiated cells do not show lowered
expression (FIGURE 4.2A). Construct 439 and construct 441 achieved 34%
and 62% knockdown of NF-YA mRNA levels respectively (FIGURE 4.2B).
Despite the incomplete knockdown, both constructs abrogated adipogenesis,
with a markedly decreased number of oil-red stained cells after
differentiation of cells (stained on day10, 7 days post induction) compared to
wild type cells or cells expressing a non-hairpin control (SCRAM) construct.
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FIGURE 4.1 Differentiation of 3T3-L1 cells. (A). Schematic summary of
differentiation protocol of 3T3-L1 cells. The red bars indicates presence of
hormonal induction. Top panel depicts oil red staining of cells in three
different time points. (B). NF-Ya expression lowers during differentiation
and remains low in mature adipocytes. (C). Two other preadipocyte
factors Klf4 and Pref1 show similar expression profile as NF-Ya. (D) and
(E). Adipogenic factors and mature adipocyte markers are induced by
initiation of terminal differentiation and remain expressed in mature
adipocytes.

These data show that adipogenesis is quite sensitive to even a modestly
reduced expression level of NF-YA (FIGURE 4.2C top panel). Cells that were
not induced to differentiate showed comparable viability versus SCRAM cells,
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showing that the defect did not affect pre-adipocyte viability and rather that
NF-YA is essential for adipogenesis (FIGURE 4.2C bottom panel). Consistent
with an effect of an NF-YA knockdown on adipogenesis, on day14, mRNA
levels of adipocyte markers C/EBPa, FABP4, LPL, leptin, and adipoQ were
reduced, further confirming that there is a defect in adipogenesis in the NFYA shRNA targeted cells (FIGURE 4.2D).
Our results showed that NF-Y expression reduces with differentiation
and that knockdown of NF-Y reduces adipocyte differentiation, both of which
suggest that it plays a role either to prime pre-adipocytes prior to
differentiation or functions early in the process before the point of adipocyte
development when it is no longer expressed. Further studies will be needed
to distinguish these possible mechanisms. Consistent with the former
possibility, NF-Y has been shown to play a role in the proliferation and
maintenance of stem cell precursors, although we failed to note any
difference in the proliferation or viability of preadipocytes after an NF-Y
knockdown (Benatti et al., 2008; Bhattacharya et al., 2003; Bungartz et al.,
2012). Moreover, since many adipocyte markers including leptin are only
expressed in mature adipocytes that are terminally differentiated, the altered
expression of a differentiated marker reflects defects during differentiation
process to some extent. Consistently, expressions of many mature adipocyte
genes are dependent on adipogenic factors PPARg and C/EBPa (Rosen et al.,
2000). While C/EBPa was shown to transcriptional activation of leptin via
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FIGURE 4.2 NF-YA Expression and Function of NF-YA in 3T3-L1 adipocytes
in vitro. (A). NF-YA mRNA is expressed at a high level in undifferentiated 3T3-L1
and its level is decreased during day3 to day7 after differentiation using a
standard cocktail of insulin, dexamethasone and IBM treatment after which NFYA remains expressed at a low level in differentiated 3T3 cells (black diamonds),
as compared to non-differentiated controls (white diamonds). (B). Two lentiviral
mediated shRNA targeting NF-YA, denoted 439 and 441, were introduced into
undifferentiated 3T3-L1. After puromycin selection, normalized NF-YA mRNA
levels were reduced by 34% and 62% in cells expressing 439 (white diamonds)
and 441 (grey squares) respectively compared to SCRAM (black circles). After
differentiation of 3T3-L1 cells, NF-YA levels become comparable in knock down
and SCRAM cells. (C) Despite an incomplete knockdown, both lines show reduced
adipogenesis after 7 days of differentiation with staining with oil-red for lipid
droplets on day10. The bottom panel shows virus-treated, non-differentiated
controls with comparable cell numbers in knocked down and non-hairpin
control cells. SCRAM indicates scramble, non-hairpin control construct. (D). The
mRNA levels of CEBPa, PPARg, LPL, leptin, and adipoQ in the shRNA knockdown
3T3-L1 were measured and normalized to housekeeping HPRT1). The
adipogenic transcription factors CEBPa and PPARg were lowered by 78%/47%
and 45%/16% in the knockdown cells, LPL was lowered by 52%/36%, and
adipokine genes leptin and adipoq were lowered by 59%/46% and 55%/32%
respectively.
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proximal promoter (He et al., 1995; Hwang et al., 1997; Miller et al., 1996), it
the functions of other distal elements that interact with C/EBP factors
remain unknown. Nonetheless, recent genome-wide study uncovered
cooperative binding of PPARg and C/EBPa at many adipocyte genes,
including non-coding regions of leptin, suggesting global transcriptional
regulation in differentiated adipocytes (Lefterova et al., 2008).
Since a total body knockout of NF-YA is lethal (Bhattacharya et al.,
2003), we generated an adipocyte-specific NF-Y knockout by crossing the
adipocyte-specific Adiponectin-CRE mouse to conditional knockout NFYA-fl/fl
mouse to study the function of NF-Y in adipocytes in animals (FIGURE 4.3A).
(In the following sections, we refer to the Adiponectin-CRE; NFYA-fl/fl mice as
NFY-KO and wildtype control NFYA-fl/fl as WT control). The knockout was
confirmed by genotyping as well as by performing western blots to assay NFYA protein expression (FIGURE 4.3A). When fed a chow diet, the NFY-KO and
WT had similar body weights beginning at weaning (3 weeks old) up until 28
weeks old (FIGURE 4.3B). However, on chow diet the NFY-KO mice showed a
significantly decreased adiposity as assessed using DEXA (p=0.002 at at 8
weeks). Furthermore, while WT mice showed an age-dependent increase in
body adiposity between 8 weeks to 28 weeks old, NFY-KO mice actually
showed a progressive loss of body fat, with an adiposity of 9.7% at 28 weeks
of age which is comparable to the fat content of lipodystrophic AZIP mice
(FIGURE 4.3C). The result was confirmed by measuring the weight of
individual epididymal, inguinal, and brown adipose tissues at different ages
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FIGURE 4.3 Generation of an Adipose Tissue Specific NF-Y Knockout.
NF-YA adipocyte specific knockout mice, NFY-KO, were generated by
crossing Adiponectin-CRE to NFYA-flox/flox mice. CRE-negative NFYAflox/flox animals are used as WT control (A). Depletion of NF-YA protein
is confirmed by western blot from adipose tissue. The NFY-KO mice
(white diamonds) have lower body weight compared to the WT control
(black diamonds) from weaning (3 weeks) to 6 weeks, but the difference
becomes insignificant afterwards, n=9 (B). NFY-KO mice (white bars)
show significantly reduced body adiposity (total fat mass divided by total
body weight) by DEXA scan with an age dependent worsening with a % fat
level consistent with lipodytrophy, n=9 (C). At 28 weeks, NFY-KO mice
show 9.7% body adiposity, comparable to the previously published AZIP
strain which shows generalized-lipodystrophic mouse model, at 10.7%
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metabolic disease. Heterozygous knockout mice, though expressing lower
level of NF-YA protein, showed no significant abnormality on body weight,
body adiposity, plasma adipokines, insulin and glucose levels (data not
shown), therefore it is not included in further investigation. It should be
noted that the shRNA knockdown in 3T3-L1 resulted in less than 50%
reduction in gene expression yet a rather dramatic impairment in
adipogenesis. The phenotypic discrepancy between 3T3-L1 knockdown and
NFY heterozygous knockout was likely due to the timing of gene ablation. In
NFY-KO mice, NF-Y gene ablation was introduced following expression of
adiponectin in mature adipocytes, while in 3T3-L1, the gene knockdown was
performed prior to terminal differentiation. This result is consistent with the
notion that NF-Y’s critical role in pre-adipocytes. In another word, using a
CRE-line expressing in preadipocyte population (which is not yet available)
will provide a comparable in vivo model to the 3T3-L1 experiment.
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Consistent with the possibility that a fat specific knockout of NF-YA
can cause lipodystrophy, NFY-KO mice showed a 2-fold decrease of plasma
leptin at 8 weeks and a 25-fold decrease in leptin level at 28 weeks with
undetectable levels of serum adiponectin at all ages tested (FIGURE 4.3E and
F). Epididymal adipose tissues were collected from 3 months old mice and
mRNA levels of various adipocyte specific genes were measured using qPCR
(Figure 4.3G). Consistent with ELISA results, the mRNA levels of adiponectin
(AdipoQ) and leptin, as well as adipsin and resistin RNAs were significantly
lowered in NFY-KO mice as were the RNAs for other adipose marker RNAs
including FABP4, PPARg, C/EBPs, CD36, Enoyl-CoA dehydrogenase (Ehhadh),
hydroxyl-CoA dehydrogenase (Hadha) and Glut4. These data showing a

FIGURE 4.4 Histology of adipose tissue in NFY-KO animals. Prominent
stromal structures in tissues from knockout animal is characteristic of
lipodystrophy. Larger yet fewer adipocytes are present in knockout tissue,
suggested possible compensatory growth of remaining cells. However, the
mechanism of such growth is unknown. All slides were prepared from 5
months old male mice.
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general decrease in the expression of a battery of adipocyte specific genes
are consistent with the adipogenesis defect observed in 3T3 cells after an NFY knockdown. Histological study of the adipose tissue showed prominent
stroma vascular structure characteristics of adipose tissue dysfunction
(FIGURE 4.4). The enlarged adipocytes in NF-YA are likely mature cells that
were not affected by the knockout and resulted in compensatory growth for
loss of total cell number. As such, progressive lipodystrophic model like this
one may be useful to study the dynamics between hypertrophy and
hyperplasia processes.
NF-Y, also known as CBP or CCAAT-binding protein, binds to the most
prevalent enhancer sequences in the mammalian genome, CCAAT, and has
been shown to be essential for a range of cellular functions including cell
cycle, proliferation, and as mentioned stem cell maintenance (Bhattacharya
et al., 2003; Bungartz et al., 2012; Dolfini et al., 2012a; Dolfini et al., 2012b;
Mantovani, 1999; Zhu et al., 2005). A whole-body knockout a NF-Y is
embryonic lethal due to a failure of cell proliferation during in utero
development, and that other pluripotent stem cells such as mesenchymal
stem cells and hematopoietic stem cells requires NF-Y to maintain their
population (Bhattacharya et al., 2003; Bungartz et al., 2012; Dolfini et al.,
2012a; Tohnai et al., 2014). In adipocytes, prior studies have only showed
that NF-Y can regulate adipocyte specific genes such as adiponectin and fatty
acid synthetic pathway in vitro (Park et al., 2004; Reed et al., 2008),
suggesting a role in mature adipocytes. Our results suggest that NF-Y also
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plays a role in pre-adipocyte (and/or an adipocyte stem cell) maintenance
and/or commitment to adipogeneis, leading to the development of an ageprogressive fat loss by and lowering of serum leptin in NFY-KO mice.
The NFY-KO animals also showed an age dependent hyperglycemia
and hyperinsulinmia. At 28 weeks old, NFY-KO mice showed 1.5-fold higher
blood glucose (p=0.001) and 10-fold higher insulin levels (p=0.01) compared
to WT (FIGURE 4.5A). Glucose tolerance tests (GTT) were next performed
showing that the NFY-KO had higher blood glucose levels at all of the time
points during the 120 minute assay (Figure 4.5B). The NFY-KO mice also
showed reduced glucose clearance with an area under curve (AUC) of blood
glucose 1.3-fold greater than WT control group (p=0.007; FIGURE 4.5C).
During GTT, the NFY-KO mice showed an ~ 4-fold higher insulin level at 30
minutes after glucose injection (p=0.03), suggesting insulin resistance
contributed to the reduced glucose clearance (FIGURE 4.5D). Finally, the
NFY-KO mice had hepatic steatosis with a 2-fold higher of triglyceride
content in liver (p=0.009, FIGURE 4.5E).
Leptin replacement has been shown to markedly improve the
metabolic abnormalities of lipodystrophy in animals and humans and a leptin
response can be considered a sine que non for this condition. To test the
effect of leptin, we treated NFY-KO animals with 350ng/hour of recombinant
leptin via osmotic pumps for 14 days (red graph in FIGURE 4.6). Control NF-Y
KO mice received PBS (black graph in FIGURE 4.6). Leptin treatment of 20
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week old NFY-KO mice normalized blood glucose at day 10 and day 14
(p=0.006 and p=0.05 respectively) compared to control mice (FIGURE 4.6A).
Leptin treatment lowered insulin level to wild-type levels (wide-type data
not shown) (p<0.01 after day 4, FIGURE 4.6B). Leptin treatment also
corrected the glucose tolerance during a GTT with a marked lowering of
blood glucose (p=0.006) and the AUC (P=0.04) (FIGURE 4.6C and D). After 14
days of treatment, the liver triglyceride content of NFY-KO was lowered by
50% (p=0.002; FIGURE 4.6E) and the total wet weight of liver was lowered
by 40% (p=0.001; FIGURE 4.6F). Cessation of leptin treatment led to a
worsening of glucose tolerance and heaptic steatosis (data not shown).
We next analyzed the effect of a high fat diet on these animals by
feeding NFY-KO and WT mice a 60% fat diet (HFD) starting at 4 weeks old.
On this diet NFY-KO mice failed to gain body weight with a statistically
different body weight compared to WT mice beginning at 7 weeks of age
(p<0.01 and p<10-5 after 11 weeks, Figure 4.7A). Similarly, DEXA
measurements for body adiposity after 6 month of HFD showed that while
WT showed a marked increase of adiposity of 40%, NFY-KO had an adiposity
of 9% which is the same adiposity that is seen when these mice are on a
chow diet (p<10-16; FIGURE 4.7B). Consistent with their low adiposity, serum
leptin remained low, between 2 to 10 ng/ml, in NFY-KO mice (FIGURE 4.7C).
The hyperglecemia and hyperinsulinemia were similar in HFD and CHOW fed
NFY-KO mice, suggesting that a lack of adipose tissue caused the metabolic
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complications and that the diet per se did not contribute to the phenotype of
the knockout mice (FIGURE 4.7D).

FIGURE 4.5 Mice with an Adipose Tissue Specific NF-Y Knockout
Develop Lipodystrophy. (A). NFY-KO mice develop hyperglycemia (red
graph) and hyperinsulinemia (blue graph) that progresses with age, n=9.
At 5 month old, NFY-KO mice show significantly higher increase of blood
glucose level. (B) The knockout caused an abnormal glucose tolerance test
(GTT) compromised glucose clearance with (C) a significantly increased
area under curve (AUC) after IP injection of 1mg glucose/g body weight
given at time 0, n=16. (D). At 30min after GTT, NFY-KO animals show 3.5fold higher insulin level compared to WT, n=7 (E). The knockout mice had
hepatic steatosis with a 2-fold increased triglyceride levels in liver tissue
of NFY-KO, n=9. NFY-KO is indicated by white and WT is indicated by
black in each result.
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FIGURE 4.6 Leptin treatment ameliorates lipodystrophy phenotypes
in 5-month-old NFY-KO mice. (A). 14 days of 350ng/hour of Leptin
treatment via osmotic pump (red graph from day0 to day14 in figure;
black graph indicates PBS treated NFY-KO animals) normalizes insulin
level and (B) blood glucose in NFY-KO mice. The difference in insulin
levels become significant after the initial response to surgery (after day 4)
and the blood glucose difference becomes significant after day10 of leptin
treatment. (C) .The GTT is normalized by Leptin at day14, with smaller
AUC (D). Liver tissues harvested from animals sacrificed on day14 showed
reduced liver triglyceride content (D left) as well as smaller overall liver
weight (D right) after Leptin treatment. The numbers of animals shown
are 10 for Leptin treatment and 7 for PBS control and age-matched 5
months old.
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To understand the mechanism of HFD-resistance in NFY-KO mice, we
measured the energy expenditure of NF-Y KO compared to WT mice using
calorimetry. Under chow diet, the NFY-KO animals showed decrease
respiratory exchange ratio (RER), suggesting that these animals utilize
primarily fat energy source as well as maintain a lower basal metabolism
(FIGURE 4.8A). Consistently, the NFY-KO animals have lowered core body
temperature (34.3˚C compared to 34.8 ˚C in WT control animals, p=0.02;
FIGURE 4.8B). However, these differences were not due decreased food
intake (data not shown). These result suggested that defect in adipose tissue
is the primary cause of low adiposity as oppose to increase energy
expenditure or physical activity.
In addition to reducing leptin expression, a knockdown of NF-Y in
vitro and a fat specific knockout in vivo also led to a general effect on
adipocyte development. This raises the possibility that NF-Y might play a
general role early in adipocyte development and functions later in
development to regulate the leptin gene. Indeed, the data are consistent with
the possibility that, together with other factors, NF-Y directly contributes to
the regulation of leptin gene expression and that the identification of factors
interacting with NF-Y could help elucidate the mechanisms controlling leptin
expression. A recent study showed that NF-Y knockout in neural cells
resulted in progressive neural degenerative disease via accumulation of
dysfunctional ER membrane (Luo et al., 2008; Yamanaka et al., 2014). Recent
studies reveal that ER stress occurs in adipocytes in obesity and diabetes
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FIGURE 4.7 NFY-KO mice are resistant to HFD. (A) The average body
weight of NFY-KO and WT animals treated with HFD (60% fat) starting
from 4 weeks old to 28 weeks old is shown, n=9. NFY-KO mice remain a
lower body weight compared to WT and the difference is significant after
6 weeks old. (B). After 6 months of HFD, the 28 weeks old NFY-KO mice
show significantly lowered body adiposity compared to matched WT
control mice, n=9. (C). NFY-KO mice did not show an increase in serum
Leptin levels compared to WT animals on the high fat diet (D) Blood
glucose and insulin levels of various age groups are shown, n=9. At 28
weeks old hyperinsulinemia and hyperglycemia are present in both NFYKO and WT mice.
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FIGURE 4.8 Calorimetric measurements of NFY-KO mice under chow
diet. (A)Oxymax data of NFY-KO and WT animals under chow diet, n=4.
NFY-KO animals show significantly lowered RER (respiratory exchange
ratio) during dark cycle, indicating that these animals utilize fat energy.
(B) During both dark and light cycles, the core temperature of NF-Y-KO
mice are lowered for about 0.5 ˚C, p=0.02 for both condition, n=8.
(Gregor and Hotamisligil, 2007; Ozcan et al., 2004); this would be a possible
mechanism by which NF-Y regulates leptin expression under different
metabolic states of adipose tissue. However, NF-Y’s general effect on adipose
cell development with lower levels of expression of adipocyte specific genes
appears to mask a specific effect on the leptin gene.
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One caveat of the in vivo studies is that the adiponetin-CRE line that
was used is not expressed until somewhat later in fat cell development
(Eguchi et al., 2011; Lee et al., 2013; Wang et al., 2010), and thus cannot be
used to assess the role of NF-Y at early developmental stages (Jones et al.,
2005). It is thus interesting that a knockout of a gene in adipocyte precursors
under the control of a promoter that is only expressed at later developmental
times (the adiponectin promoter) can have a dramatic effect on adipocyte
mass with an age- dependent worsening of lipodystrophy between 4 and 28
weeks. One possible explanation is that an NF-Y knockout also has an effect
on mature adipocytes that leads to reduced replenishment of adipocytes as
they turnover (Arner and Spalding, 2010a). This would explain the
worsening of the lipodystrophy with age compared to the normal trend of
mice to gain fat mass as they get older. It has been previously suggested
using a model of inducible lipodystrophy mouse models that total pool of
adipocytes is finite (Pajvani et al., 2005; Wojtanik et al., 2009). As such, if
there were a defect in adipogenesis and/or a faster turnover of the knockout
adipocytes in NFY-KO mice, the adipose tissues would be depleted over time
manifesting in a progressive lipodystrophy similar to that which we
observed. It should also be noted that when adiponectin-CRE mice are used to
generate PPARg and Raptor adipocyte specific knockout mice, the knockout
animals are lean, resistant to a high fat diet, but metabolically healthy and do
not show signs of lipodystrophy (Jones et al., 2005; Polak et al., 2008). The
phenotypic difference between these mouse models and ours suggests that
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NFY could play a prominent role to specifically control leptin expression, in
addition to its more general role in fat cell development. NFY could also play
a functional role in preadipocytes, thus a knockout could exacerbate
depletion of adipocytes by disruption of the generation and/or maintenance
of a preadipocyte pool. This possibility is supported by our observations in
3T3-L1 preadipocytes, as well as other studies where NF-YA was shown to be
crucial for cell proliferation and stem cell maintenance (Bhattacharya et al.,
2003; Bungartz et al., 2012; Dolfini et al., 2012a).
Thus one possible mechanism for the lipodystrophy in NF-Y KO mice
could be that there is a population of adipocyte precursors that expresses
adiponectin, and that NF-Y ablation in this population compromises the
ability of animals to replace adipocytes over time. Indeed, recent studies
report expression of late adipogenic genes including FABP4 and adiponectin
in a population of preadipocytes in the stromal vascular fraction where
adipocyte precursors reside (Berry and Rodeheffer, 2013b; Shan et al., 2013) .
In addition, adiponectin expression can be detected during early
development at E14 (Birsoy et al., 2011; Wang et al., 2013b). The possibility
that lipodystrophy is a result of gene ablation in preadipocytes is also
supported by a previous published lipodystrophy mouse model in FPLD
(Dunnigan’s familial partial lipodystrophy). The FPLD mouse was generated
by expressing a dominant negative form of LMNA, the major component of
nuclear lamina, using the aP2 promoter (Wojtanik et al., 2009). The FPLD
mice showed progressive fat loss and metabolic complication manifesting
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lipodystrophy in human patient with the same genotype. Further, primary
culture isolated from FPLD mice showed impaired adipogenesis in vitro. The
FPLD mice and NFY-KO mice are phenotypically similar mouse models in
that both are expressed later in development but also develop a more
profound defect in adipogenesis than would be expected from an effect only
on mature adipocytes.
The importance of the early stages of adipogenesis is also highlighted
by data from a patient with congenital generalized lipodystrophy who had a
de novo, homozygous point mutation in the promoter of c-fos (Knebel et al.,
2013). In 3T3-L1 cells, c-fos expression peaks at early times during hormone
induction, which then modulates expression of other downstream
proadipogenic factors during differentiation (Distel et al., 1987; Rangwala
and Lazar, 2000). Genome wide in silico analysis showed co-localization of
FOS and NF-Y, but whether this interaction has biological relevance in
adipose tissue will require further investigation (Fleming et al., 2013). The
importance of early transcriptional events is also supported by our findings
for NF-Y which is also expressed only early in adipogenesis and can cause
lipodystrophy in homozygous knockout mice. It is also possible that other
mutations in NF-Y can act in a dominant negative manner as it has been
shown that a dominant negative form NF-Y suppresses c-jun activity, a
transcription factor that is also important for early adipogenesis (Nabokina
et al., 2013; Rangwala and Lazar, 2000; Tiwari et al., 2012).
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Several possible mechanisms for the pathologic loss of adipose tissue
and lipodystrophy have been identified in both human and mouse models
though none have appeared to have a specific role on leptin production. For
instance, lipodystrohpy can be caused by an autosomal recessive mutation in
AGPAT2, an acyltransferase highly expressed in adipose tissues and
important for triglyceride synthesis, which leads to an imbalance in fat
storage and lipolysis (Luckman et al., 1999; Rosenblum et al., 1996;
Rosenblum et al., 1998). A dominant mutation of PPARg can cause human
lipodystrophy, as the mutant PPARg showed reduced transcriptional activity
with a reduced rate of adipogenesis (Rosenbaum et al., 1996; Zhang et al.,
2014). The fld mice (fatty liver dystrophy), a spontaneous form of
lipodystrophy in mice, results from a point mutation in lipin-1(Peterfy et al.,
2001). Lipin-1 is a phosphatase that plays a role in triglyceride metabolism
and transcriptional co-activation of PPARg during adipogenesis (Reue and
Dwyer, 2009). Both dominant and recessive mutation of LMNA (the
aforementioned FPLD mouse) causes lipodystrophy potentially due to its
involvement in nuclear lamina that regulates nuclear trafficking and
transcriptional activity (Schmidt et al., 2001; Wojtanik et al., 2009). Further
studies will be needed to determine whether NF-YA interacts with any of
these or other factors that play a role in adipocyte development and/or that
can contribute to the development of lipodystrophy. It should be noted that
the lipodystrophy can also be acquired resulting from what appears to be an
immune mechanism or more recently in HIV patients on triple therapy that
90

includes protease inhibitors (Schott et al., 2004). Lipodystrohy can be the
result of defective adipogeneis and/or an increase rate of loss of of mature
adipocytes which then secondarily lead to a reduced leptin level. This
condition is distinct from leanness, in which adipose tissue mass is reduced
in the absence of metabolic disorders. Lipodystrophy is caused by a relative
deficiency of leptin. Thus while fat cell transplants from wild type to
lipodystrophic mice can correct this condition, transplants of leptin deficient
adipose tissue cannot (Tran and Kahn, 2010). The fat loss in the NF-Y KO
mice while significant is not as severe as it is in other etiologic forms (such as
AZIP model) raising the possibility that the NF-Y KO could have a
disproportionate effect to decrease leptin production.
In summary of Chapter 3 and Chapter 4, In addition to establishing a
role for NF-Y in adipocyte development in vivo and as a potential cause of
lipodystrophy, these data also provide a framework for dissecting the
regulation of the leptin gene. In unpublished studies we have identified other
factors that interact with the leptin gene raising the possibility that leptin is
regulated by a transcription complex of which NF-Y is a component,
potentially through both sequence specific and non-specific mechanisms. The
elucidation of the underlying transcriptional mechanisms by which NF-Y
controls leptin gene expression could thus lead to the identification of a lipid
sensing mechanism in fat cells that modulates adipocyte function and leptin
production in response to changes in adipocyte lipid content.
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TABLE 4.1 Weight of different organs of NFY-KO and WT control at various ages.
Testicles

Kidneys

Liver

Spleen

KO

WT

KO

WT

KO

WT

KO

WT

3 mon

214±12

211±36

419±26

406±31

1408±94

1282±116

110±22

86±7

5 mon

239±10*

213±8

439±8

422±5

1972±100**

1441±30

121±17

116±12

7 mon

212±25

234±15

572±66*

422±24

1970±510

1573±106

208±63

94±3

Pancreas

Lung

Heart

KO

WT

KO

WT

KO

WT

3 mon

250±41

193±8

193±8*

167±8

215±27

242±26

5 mon

398±92*

185±12

222±21

171±17

260±6**

186±7

7 mon

508±140

251±23

367±85*

176±9

251±19*

185±23
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CHAPTER 5: ES-CELL COMPLEMENTATION
5.1 Introduction
Based on the lipostatic viewpoint of energy homeostasis, adiposity
level serves as a gauge for body energy availability. By modulating leptin
production, adipose tissue signals the central nervous system to adjust food
intake and energy expenditure, which are physiological and behavioral
responses aiming to maintain adiposity homeostasis. As such, adipose tissue
size control is central to energy homeostasis in animals. The collection of
studies on adipose tissue development in humans and rodents suggests a
framework of coordinated hypertrophy (increase in cell size) and
hyperplasia (increase in cell number) in determining body adiposity. Under
healthy conditions, total adipocyte number in an animal remains close to
constant after the adolescence period (Greenwood et al., 1979; Greenwood
and Hirsch, 1974; Knittle and Hirsch, 1968) and the average size of
adipocytes also stabilizes in early adulthood (Hemmeryckx et al., 2010; Stiles
et al., 1975). This leads to the hypothesis that the plateau in adipocyte
number in adult animals is determined and controlled by their
developmental program. Restoration of adipose tissue following lipectomy
(surgical removal of adipose tissue) in rodents and humans further suggests
that total adiposity is regulated (Espejel et al., 2010; Hernandez et al., 2011;
Huang-Doran et al., 2010; Reyne et al., 1983). Experiments that studied
adipose tissue cellularity in juvenile rats demonstrated compensatory
growth to generate the same total number of adipocytes as control animals,
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which was not observed when the same manipulation was performed on
adult rats (Faust et al., 1977a, b). Nutritional manipulation by altering litter
size during early development leads to a decrease in adipocyte numbers
(Knittle and Hirsch, 1968), yet starvation and refeeding of non-obese adults
do not affect the total adipocyte number (Hirsch and Han, 1969; Yang et al.,
1990). Additionally, it was recently shown that mature adipocytes turn over
at a constant, albeit slow, rate in both adult humans and mice (Spalding et al.,
2008; Wang et al., 2013b). In sum, these results suggest developmental
programming in determining adipocyte cell number, which is maintained
through a fine balance of adipogenesis and adipocyte death. The mechanism
involved in regulation of adipocyte cell number and coordination of
adipocyte hypertrophy together in determining total adiposity is largely
unknown.
The plasticity of adipose tissue is most prominent in the case of
obesity. Several studies have investigated the relative contribution of
hypertrophy and hyperplasia to achieve massive adipose tissue accumulation
in obesity, with varying results. The presented data consistently showed
significant contribution of hyperplasia in early-onset obesity, prior to the
developmental establishment of adipocyte number (Lemonnier, 1972; Salans
et al., 1973), however, it remains in debate whether hyperplasia also
contributes to late-onset obesity. Nonetheless, given the upper limit on
adipocyte size (Leonhardt et al., 1972), which would limit adipose tissue
expansion by hypertrophy alone, it is assumed that hyperplasia must
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accompany hypertrophy at least in cases of extreme obesity. Mathematic
modeling on total fat mass versus mean adipocyte volume supports this
conclusion (Jo et al., 2009; Spalding et al., 2008). Additionally, the extent of
hyperplasia contribution to adipose gain appears to be dependent on many
factors including sex, genetic background, genetic versus dietary causes of
obesity, as well as timing of the assay and the specific adipose depot of
question. A recent study using AdipoChaser mice demonstrated that the
appearance of new adipocytes in visceral adipose tissue under HFD much
precedes that in the subcutaneous compartment (Lee et al., 2012; Wang et al.,
2013b), while another study showed that HFD induced a higher adipogenic
capacity in subcutaneous rather than visceral adipose tissue (Joe et al., 2009).
Expansion of adipose tissue in response to HFD is critical to the metabolic
health of animals. Under positive energy balance, adipose tissue not only
stores energy for future use but also ensures that the storage is in a safe form.
However, since the capacity of adipose stores is finite, sustained energy
balance results in failure of adipose tissue to accommodate surplus energy as
fat and results in lipotoxicity in other peripheral tissues. Such an
“expandability” model (Virtue and Vidal-Puig, 2008) is supported by studies
of human and mouse models on the opposite ends of the obese spectrum.
Both lipodystrophy (with a very limited adipose capacity) and morbid
obesity (with a very large capacity yet deficit compared with chronic energy
surplus) represent conditions of stressed and unhealthy adipose tissue, thus
various metabolic conditions ensue. Thus, it is possible to ameliorate insulin
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resistance in the face of obesity by increased capacity of adipose tissue,
which has been demonstrated by crossing adiponectin-overexpression mice
to ob/ob (Kim et al., 2007).
The mechanism by which obesity affects adipogenesis in vivo is also
not clear, although the observation of similar turnover rates of adipocytes in
obese and non-obese adults suggested that the state of obesity alters the
adipocyte number set point (Spalding et al., 2008). Several HFD feeding
studies have demonstrated that the appearance of new adipocytes coincides
with existing adipocytes reaching their maximal size (Faust et al., 1978; Joe et
al., 2009; Wang et al., 2013b). Although it has been shown that paracrine
activity of mature adipocytes can affect adipogenesis (Janke et al., 2002;
Marques et al., 1998), the details of these processes are not well understood.
Adipose tissue, as a whole, is an essential regulatory component in energy
homeostasis acting as both an energy reservoir and an endocrine organ.
Moreover, it appears that adipocyte cellularity is predictive of whole-body
metabolic health in obesity, in which hypertrophy is an independent risk
factor for insulin resistance and T2DM regardless of BMI (Arner et al., 2010;
Lonn et al., 2010; Weyer et al., 2000). Altogether, studying the mechanisms
controlling adipocyte hypertrophy and hyperplasia is instrumental to our
approach in viewing adipose tissue as a metabolism organ as well as
understanding pathogenesis of obesity and metabolic diseases.
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This chapter describes a series of experiments employing a novel
blastocyst complementation assay to elucidate the molecular mechanisms
that control adipose tissue deposition in mice in vivo. Specifically, wild-type
embryonic stem cells (ES cells) are injected into the blastocysts of AZIP
lipodystrophic mice (FIGURE 5.1). When pluripotent wild-type ES cells are
injected into AZIP blastocysts, the resulting chimeras (AZIP-chimera) are
expected to have restored adipose tissue and rescued AZIP phenotypes. As
the AZIP blastocyst is defective in adipogenesis, such a developmental defect
is complemented by the progeny of pluripotent ES-cells. By necessity, the
adipocytes in AZIP-chimera are exclusively derived from injected ES cells.
Since the ES cells are incorporated into the embryo and will contribute to all
lineages including adipocyte precursors, this method allows us to observe
the earliest developmental processes of adipogenesis in vivo. To date, there is
no other tool capable of specific manipulation of early adipogenesis in vivo,
since the nature of these stages is largely unknown.
Similar blastocyst complementation assays have provided unique
tools to test the ability of a mutant to form the cell type or organ in question.
These are effective in vivo systems not only to study the developmental
processes but also to study the effect of a genetic defect on adult tissues.
Some examples include studies on lymphocytes (Chen et al., 1993), ocular
lens (Liegeois et al., 1996), liver (Espejel et al., 2010), pancreas (Jonsson et al.,
1994), muscle (Cote et al., 1999), and CNS (Low et al., 2009). Analysis of cell
lineage in chimeric tissues allows the distinction of cell-autonomous and
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FIGURE 5.1 Generation of AZIP-chimera by ES-cell complementation
into AZIP blastocysts. AZIP transgenic animals possess lipodystrophic
phenotype with complete lack of white adipose tissue (see right side
photo). Multipotent wild-type ES-cells are injected into AZIP blastocysts,
which will complement the lipodystrophic phenotype and restore adipose
tissue exclusively derived from ES-cells. Photograph of animals adapted
from Life without white fat: a transgenic mouse (Moitra et al., 1998).

non-cell-autonomous effects of the mutant. A prominent example is the study
on developmental determinant of pancreas and liver sizes (Stanger et al.,
2007). In such case, wild-type ES cells were injected into blastocysts of
apancreatic Pdx1-deficient mice. The resulting chimeras are restored with a
pancreas. However, the size of the restored pancreas is limited by the
number of injected progenitor cells. In contrary, liver size is not limited by
the number of progenitor cells and other intrinsic factors dictate its final size
(Stanger et al., 2007). In a preliminary study, we determined the relationship
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between the number of progenitor cells and whole body adipose content and
showed that adult adiposity under normal conditions is independent of
progenitor number. This is consistent with various prior studies using
individual animals that adiposity is maintained by some intrinsic
mechanisms during external perturbations. Notably, HFD can be viewed as
an external challenge under which adipose tissue responds with
hypertrophic and hyperplastic expansion. Using AZIP-chimeric mice with
varying chimerism, this part of the thesis discusses how predisposition of
limited progenitor affects adipose tissue expansion during HFD exposure.
Previous examples of a loss-of-function study of PPARg in
adipogenesis utilized a similar approach. Homozygous knockouts of PPARg
do not survive past embryonic day 10 due to a defect in placental
development (Barak et al., 1999; Kubota et al., 1999). To circumvent this
problem, one approach was to create an aggregation of chimeras derived
from wild-type ES cells and homozygous PPARg knockout ES cells (Rosen et
al., 1999). The result demonstrated that PPARg is required for adipogenesis
in vivo by showing exclusion of knockout cells from adipose tissue, but not
several other tissues. The alternative approach was to create chimeric
embryos using wild-type tetraploid cells, which allow rescue of the placental
defect, and PPARg knockout ES cells, which are the sole contributor to the
embryo proper (Barak et al., 1999). Unfortunately, this resulted in only one
live birth with a brown adipose tissue defect and died shortly after birth. In
the second part of our study, we demonstrate the utilization of our ES99

complementation model in the study of adipogenesis in vivo by first
performing the proof-of-principle experiment with PPARg knockout cells.
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5.2 Results and Discussion
AZIP (FVB) chimeras were generated by injecting B6-Tyrc-YFP mouse
ES-cells into 3.5-day blastocysts from breeding of wild-type FVB females to
AZIP(FVB) transgenic males. Since both the blastocyst and the ES-cells (both
harboring homozygous Tyrc alleles) have white coat color, AZIP(FVB)
chimeras are completely albino. Within the AZIP positive group, 11 males
carried YFP genotype, which indicated these are AZIP(FVB) chimeric mice
with composed of both AZIP-positive cells and YFP-positive cells.
Alternatively, the B6-ES cell derived cells can be distinguished from FVBblastocyst derived cells at agouti locus, where FVB strain carries the alleles
for agouti A/A and B6 strain carries nonagouti a/a. However, we did not
employ this genotyping strategy, nor did we compare measurements for
chimerism using different loci. In practice, degree of chimerism of these
AZIP-chimeric mice was determined by the percent of YFP-genotype cells
comparing to a genomic locus common to both strains, fabp4, in DNA sample
extracted from whole blood samples. This approach was rationed that, since
adipose tissue are always 100% ES-cell contributed (see below) and that
different developmental lineages may demonstrate variability in EScontribution (Kusakabe et al., 1988), a tissue type that is closely related to
adipose tissue should be used as a surrogate for chimerism in preadipocyte
population. In addition, this surrogate tissue is best collected via simple, noninvasive biopsy. Since adipocytes are generally considered mesenchymal
linage along with muscles, endothelial cells, osteoblasts, and blood cells, we
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FIGURE 5.2 Correlation between degrees of chimerism measured in
genomic DNA of subcutaneous adipose tissue versus whole blood of
WT-chimera. Chimerism is defined as amount of YFP genes (carried by
ES-cells) out of amount of FABP4 gene (carried by both ES-cell and
blastocyst).

hypothesized that DNA extracted from whole blood could represent the
genotype composition of DNA from adipose-lineage tissues. This hypothesis
was tested by comparing DNA samples of wild-type chimeric animals (i.e.
chimeric mice produced by combing wild-type ES cell and wild-type
blastocyst), which are chimeric for every tissue including adipose tissue and
blood (FIGURE 5.2). Our hypothesis is confirmed, because the percentage of
YFP-cells in adipose tissue in wild-type chimeras highly correlated
(R2=0.6968) to the percentage measured in whole blood samples. Using this
method, we measured the degree of chimerism of 11 AZIP(FVB) chimeric
male mice, and summarized the result in TABLE 5.1. Sectioning of the
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FIGURE 5.3 Immunohistology of adipose tissue from one AZIPchimeric animal. The tissue is fixed in 4% PFA and paraffin embedded
before sectioning. FABP4 staining indicates white adipocytes, which
colocalized with YFP staining for ES cells.

adipose tissue collected from one of the chimeras showed 100% YFP mature
adipocytes (FIGURE 5.3).
Lack of adipose tissue in AZIP transgenic mice results in severe
metabolic complications, including hyperglycemia, hyperinsulinemia,
hyperlipidemia, and liver steatosis (Moitra et al., 1998). Moreover, it has
been shown that surgical transplantation of adipose tissue (Colombo et al.,
2002; Gavrilova et al., 2000; Tran and Kahn, 2010) and isolated adipocyte
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progenitor cells (Rodeheffer et al., 2008) rescue these metabolic phenotypes,
primarily by restoration of adipokine secretion (Colombo et al., 2002). In the
AZIP-chimeric animals, adipose tissue was restored by providing ES-cells
capable of adipogenesis in vivo. As such, the lipodystrophic defects caused by
AZIP-transgene can be complemented and the metabolic phenotypes can be
rescued if the ES-cells developed into functional adipocytes in the chimeric
mice. At 8 weeks of age, all 11 out of 12 AZIP(FVB) chimeric mice showed
normalized blood glucose from 580±12 mg/dL in AZIP(FVB) transgenic
animals that are not complemented (n=10; labeled “uncomp.”) to 166±6
mg/dL in complemented chimeric animals (n=11), p=3x10E-7 (FIGURE 5.4A).
Age matched wild-type chimeric mice have blood glucose 167±7 mg/dL
(n=9), which showed no significant difference with the complemented group.
One additional chimeric mouse with 2% chimerism was hyperglycemic and
leptin deficient, suggesting that the ES-cell did not complement adipocyte
development in this animal. Compared to hyperinsulinemia AZIP(FVB) mice,
which have plasma insulin of 9.3±0.4 ng/mL (n=5), AZIP(FVB) –chimera have
significantly lowered insulin level of 3.5±0.9 ng/mL (n=11; p=2x10E-4).
Wild-type chimeric mice have 0.8±0.2 ng/mL plasma insulin (n=7), which is
slightly lower than AZIP-chimeric group with p=0.05 (FIGURE 5.4B).
Euglycemia accompanied by potential hyperinsulinemia in complemented
animals suggested partial insulin resistance and only partial rescue of AZIP
phenotypes by wild-type ES cells. Body adiposity as measured by DEXA and
serum leptin levels do not correlate with degree of chimerism, ranging from
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FIGURE 5.4 Metabolic phenotypes of AZIP(FVB)-transgenic animals.
Hyperinsulinemia and hyperglycemia are rescued by YFP-labled ES-cell
complementation in AZIP(FVB)-chimeras. All animals depicted are live
born from blastocyst injection and categorized into three groups:
AZIP(uncomp.) as AZIP animals without ES-cell contribution, AZIPchimera as animals carrying both AZIP-cells and YFP-cells, and WTchimera as animals carrying wild-type FVB cells and ES cells. (A). Blood
glucose in AZIP-chimera is significantly lowered from 580 mg/dL in
AZIP(uncomp.) to 166 mg/dL (p=3x10E-7). WT-chimeras have similar
blood glucose level of 167 mg/dL. (B). Insulin in AZIP-chimeras is lowered
from 9.3 ng/mL in AZIP(uncomp.) to 3.5 ng/mL (p=2x10E-4), yet this
level is slightly elevated compared to 0.8 ng/mL in WT-chimera (p=0.05).
n=10 for AZIP(uncomp.), n=11 for AZIP-chimera, and n=9 for WTchimera.

1% to 97% in both AZIP- and WT-chimeras (FIGURE 5.5A and B). Moreover,
body adiposity measurements correlate with leptin levels in both groups of
chimeras, where the degrees of correlation are identical between the groups
(FIGURE 5.5C). The three groups of animals showed no difference in total
body weight from 4 to 13 weeks old (FIGURE 5.5D). This suggested that body
adiposity and leptin level are controlled by adipocyte autonomous factors
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FIGURE 5.5 Relationships between degrees of chimerism, body
adiposity, and serum Leptin levels in AZIP(FVB)-chimeric animals.
Wild-type chimeric animals, which are chimeras that do not carry AZIP
transgenes and therefore are chimeric at every tissues, are plotted in
white diamonds, while AZIP-chimera are depicted in black diamonds.
Degree of chimerism does not affect serum Leptin levels (A) nor body
adiposity (B). Leptin level is correlated with body adiposity in chimeric
animals (C), as would be expected in normal animals. (D). Both groups of
chimeric animals showed no difference in body weight compared to
AZIP(uncomp.) mice (green squares) generated from microinjection.

and that limitation on progenitor number per se does not affect adiposity
under normal condition.
Similar insulin resistance phenotype was observed in AZIP-animals
underwent either transplantation of wild-type adipose tissue or leptin
replacement (Colombo et al., 2002). On the other hand, ob/ob mice treated
with leptin showed complete normalization on insulin level. Together these
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results demonstrated that while lack of adipocytes and leptin are the primary
defect to insulin resistance, additional factors of adipose tissue that are
missing in AZIP and/or other tissues remain important in glucose
metabolism. In AZIP-chimeric mice, the only cell type completely derived
from ES cells is mature adipocytes. As such, it is concluded that cellautonomous factors of mature adipocytes cannot fully rescue the metabolic
defects caused by AZIP transgene. Non-cell-autonomous factors such as
AZIP-associated defect in the stroma vascular fraction (SVF) of adipose tissue
and in liver and muscle tissues can affect glucose metabolism. For instance, it
has been shown that the residual adipose tissue of AZIP-mouse, consisted of
primary SVF, presents a hyperadipogenic niche (Berry and Rodeheffer,
2013b; Birsoy et al., 2008a). Moreover, it has been shown that certain
population of isolated wild-type preadipocytes showed varied adipogenic
capacity when transplanted into AZIP or wild-type mice (Berry and
Rodeheffer, 2013a), suggesting non-adipocyte autonomous factors in SVF
that can alter the cellularity and functioning of whole adipose tissue, despite
all the mature adipocytes are wild-type. Since AZIP-transgene is expressed
under adipocyte specific aP2-promotor, it is also unclear whether the
phenotype is a result of leaky expression. Previous study has demonstrated
the promiscuity of aP2-promotor in other tissues and especially during
development (Lee et al., 2013), therefore it is possible that early
developmental events contribute to the observed metabolic phenotypes in
adult animals.
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The AZIP(FVB) blastocyst complementation experiment provided the
preliminary validation of the method. However, we experienced difficulties
when manipulating the AZIP(FVB) blastocysts, which developed poorly in
vitro after isolation at morula stage. We suspected that FVB-background was
not ideal for embryo manipulation and it was not compatible with B6backgroung of ES-cells (Schuster-Gossler et al., 2001). Additionally, B6 is the
common strain employed in HFD study and it the best characterized in
metabolism (West et al., 1992). Thus, to study effect of HFD on adipose tissue
accumulation in chimeric animals, we generated a separate set of chimeric
mice using AZIP(B6)-blastocyst and B6-Tyrc-YFP ES-cell. These chimeric
animals carried inbred B6 genetic background in all cells, thus also avoided
potential complication due to background variability.
We analyzed 17 AZIP(B6)-chimeras and compared the results to 17
AZIP(B6) transgenic mice and 19 WT(B6)-chimeras generated as littermates
from blastocyst injection experiments. While AZIP(B6) transgenic mice
showed lowered body weight at weaning (3 to 4 weeks old) compared to
both chimeric groups, no difference was detected among the three groups in
adult animals (FIGURE 5.6). At 12 weeks old, AZIP-chimeras showed
10.0±0.6% body adiposity measured by MRI, which was indistinguishable
from that of AZIP-uncomplemented animals at 8.9±0.3% but significantly
lowered compared to WT-chimeras at 16.9±0.4% (p=10E-4; FIGURE 5.7A
and B). The same comparisons were observed for adiposity measured at 24
weeks old, where AZIP-chimeras showed 11.0±0.9%, AZIP showed 9.2±.4%,
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FIGURE 5.6 Body weight of animals from AZIP(B6) blastocyst
complementation. AZIP(uncomp.) showed lowered body weight
between 3 and 4 weeks (p=0.008 and 0.01 respectively), but no difference
is detected among all groups in other age measured. n= 17 for
AZIP(uncomp.) showed in black squares, n=17 for AZIP-chimera showed
in blue squares, and n=19 for WT-chimera showed in white squares.

and WT-chimeras showed 20.9±0.1%, n=15, 13, 18 respectively due to
mortality (FIGURE 5.7C and D). Difference between AZIP-chimeras and WTchimeras remained significant with p=2x10E-4. Scattered plot of adiposity
versus degree of chimerism showed that AZIP-chimeras are leaner than WTchimeras across the board (FIGRUE 5.7B and D). Consistently, at 12 weeks
old, AZIP-chimeras have lowered serum leptin levels at 5.25±0.97ng/mL
compared to that of WT-chimeras at 10.45±1.49ng/mL (p=6x10E-3).
Nonetheless, AZIP-chimeras showed significant rescue of leptin deficiency
phenotype of AZIP-uncomplemented mice, in which serum leptin levels were
below detection limit (FIGURE 5.7E and F). In both AZIP- and WT-chimera
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FIGURE 5.7 Body adiposity and serum leptin of AZIP(B6) animals. All
animals presented are pups of blastocyst complementation. (A). Body adiposity
at 12 weeks old measured by MRI, where AZIP(uncomp.), AZIP-chimera, and WTchimera have 8.9%, 10.0%, and 16.9% adiposity respectively. AZIP(uncomp.)
and AZIP-chimera are indistinguishable while both are significantly lowered than
WT-chimera (p=10E-4). (B). Adiposity at 12 weeks old versus chimerism in
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FIGURE 5.7 (cont.) AZIP-and WT-chimeras. AZIP-chimera show lower adiposity
across all range of chimerism. (C). and (D). Body adiposity at 24 weeks old. (E).
Serum leptin in three groups of animals. AZIP(uncomp.) has undetectable level of
leptin. AZIP-chimera has 5.25 ng/mL leptin, which is lowered compared to that
of WT-chimeras at 10.45 (p=6x10E-3). (F). Serum leptin versus chimerism in
chimeric animals shows that AZIP-chimeras have lowered leptin across all range
of chimerism.

leptin level does not correlate with chimerism. Two WT-chimeras with high
leptin levels were excluded based on outlier tests.
Next, we examined whether metabolic complications in
lipodystrophic AZIP-transgenic mice can be rescued by complementing
adipogenesis defect with ES-cells. Hyperinsulinemia at 12 weeks old due to
adipose tissue defect in AZIP-transgenic mice was rescued in AZIP-chimeras,
from 111±11ng/mL to 8±4ng/mL (p=5x10E-12). Insulin level in AZIPchimeras is slightly elevated compared to WT-chimeras at 1.84±0.24ng/mL,
p=10E-2 (FIGURE 5.8A). Insulin level was inversely correlated with
chimerism in AZIP-chimeras but not WT-chimeras (FIGURE 5.8B). Moverover,
insulin level was also inversely correlated with body adiposity in AZIPchimeras but not WT-chimeras, suggesting that the incompletely rescued
metabolic phenotype was secondary to adiposity defect (FIGRUE 5.8C). On
the other hand, no significant difference in blood glucose at 12 weeks old was
detected among groups, primarily because AZIP(B6) animals, as previous
reported (Colombo et al., 2003; Haluzik et al., 2003), were not hyperglycemic
to start with (FIGURE 5.8D). Liver steatosis prominent in AZIP(B6) mice, as
measured by total liver weight (Colombo et al., 2002), was rescued by
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FIGURE 5.8 Metabolic phenotype in AZIP(B6) animals. (A). Insulin levels at
12 weeks old. AZIP(uncomp.) mice are hyperinsulinemic at 111 ng/mL, while
insulin level is significantly lowered in AZIP-chimeras at 8 ng/mL (p=5x10E-12),
which remain slightly elevated compared to WT-chimera at 1.8 ng/mL (p=10E2). (B). And (C). Insulin level is inversely correlated with chimerism and body
adiposity. (D). Blood glucose in each group of animals at 12 weeks old. Despite
having elevated insulin levels, AZIP-chimeras showed wild-type level of blood
glucose. (F). And (G). Liver steatosis as measured by total liver weight. Liver
weight is comparable in AZIP-and WT- chimeras across all range of chimerism.

112

complementation, where liver of AZIP-chimera weighed 1786±48mg (n=4)
and liver of AZIP-uncomplemented mice weighted 6058±479mg (n=5),
p=10E-4. Liver of WT-chimeras weighted 1505±125mg, with no
distinguishable difference compared with AZIP-chimeras independent of
chimerism (FIGURE 5.8E and F).
The observations that AZIP-chimeras remained slightly lipodystrophic
and leptin deficient suggested that partial adipose tissue defect was the
primary cause of insulin resistance. This is consistent with observation in
human patients where metabolic complication is in general correlated with
extent of adipose tissue loss (Huang-Doran et al., 2010). In AZIP-chimeric
model, since all mature adipocytes are derived from wild-type progenitors,
this may reflect non-adipocyte autonomous factors that contributed to
dysfunction of adipose tissue. For instance, insulin resistance in adipocytes
can lead to defective adipogenesis and lipid accumulation, which can lead to
lipotoxicity in other tissues despite only moderate lipodystrophy (Laustsen
et al., 2002; Rosen and Spiegelman, 2000). Impaired glucose metabolism in
adipose tissues, such as in case of early stage T2DM, is primary to
development of insulin resistance in muscles and liver (Abel et al., 2001;
Shepherd and Kahn, 1999). By this mechanism, it is postulated that AZIPchimeric mice became moderately insulin resistant despite having
adipocytes restored. Whether AZIP-transgene, which is expressed in varying
degree in other tissues of the chimeras, directly affects other tissues remains
unclear. Although previous report suggested PPARg down-regulation in liver
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of AZIP-transgenic model as a mechanism of liver insulin resistance
(Gavrilova et al., 2003), it cannot be deduced from such case if it originated
from a liver-autonomous defect. Alternatively, reduced plasma leptin itself
can result in hyperinsulinemia, because leptin has been shown to negatively
regulate insulin secretion as part of the adipoinsular axis (Kieffer and
Habener, 2000; Kulkarni et al., 1997).
Next, we place AZIP- and WT-chimeric animals on HFD treatment to
assay whether limited adipocyte progenitors in AZIP-chimeric mice limits
diet induced obesity. After 6 weeks of HFD starting from 6 weeks old, AZIPchimeras showed averaged 47.3% of weight gain (n=14), which is
significantly lower than 78.8% weight gain of WT-chimeras (n=11; p=5x10E3). Comparing to WT-chimeras, AZIP-chimeras with low chimerism gained
less weight (FIGURE 6.9A and B). A subset of these animals that were
littermates were further studies on change in body adiposity and insulin
levels after HFD. Body adiposity elevated by 5.7% in AZIP-chimeras (n=7),
which is significantly lower than the elevation of 21.2% in WT-chimeras
(n=10; p=8x10E-5). Similar to total body weight, low-chimerism correlated
with less adipose tissue accumulation in AZIP-chimeras but not in their WTcounterparts (FIGURE 6.9C and D). Insulin resistance developed more readily
in AZIP-chimeras than WT-chimeras, where insulin levels were
3.17±0.95ng/mL and 0.95±0.25ng/mL respectively (p=10E-2) while glucose
levels were comparable (FIGURE 6.9E, F and G). Interestingly, serum leptin
correlates with body adiposity measured after 6 weeks of HFD in both AZIP114

FIGURE 5.9 AZIP(B6)-chimeras are resistant to obesity but not metabolic
complication of HFD. (A). Percent of total weight gain after 6 weeks of HFD
(from 6 to 12 weeks old). AZIP-chimeras on average gained 47% weight while
WT-chimeras gained significantly more, 79% (p=3x10E-3). (B). Analysis on
percent weight gain versus chimerism shows that, at lower chimerism, WTchimeras gained more weight than AZIP-chimeras. n=14 for AZIP-chimera and
n=11 for WT-chimera. (C). Analysis of a subset of littermate chimeras on body
adiposity change after 6 w of HFD. AZIP-chimeras (6%) accumulated less fat
mass compared with WT-chimeras (21%), p=8x10E-5. (D). Change in adiposity

115

FIGURE 5.9 (cont.) versus chimerism shows that AZIP-chimeras with low
chimerism is defective at accumulate fat mass. (E). Insulin levels of HFD-treated
chimeras shows AZIP-chimeras are more susceptible to development of insulin
resistance. (F). Blood glucose of HFD-treated chimeras shows no difference in
glucose level in AZIP-and WT-chimera. For figure (C) to (F), n=7 for AZIPchimeras, and n=10 for WT-chimeras.

and WT-chimeras (FIGURE 5.10). In summary, the result suggested that
leptin production is a cell-autonomous property of adipocytes, adipose tissue
expansion and metabolic complications as a result of adipose tissue defect
are not adipocyte-autonomous.
There are two possible explanations for the apparent resistance to
HFD observed in AZIP-chimeric animals. Since adipose tissue expansion is
accompanied by hypertrophy and hyperplasia (Arner and Spalding, 2010b),
defects in either or both processes can lead to failure in adipose tissue
accumulation. If AZIP-chimeric adipose tissue is insulin resistant as
previously discussed and since insulin signaling is required for lipid
accumulation in adipocytes (Yu et al., 2008), AZIP-chimeras will not become
obese on HFD through hypertrophic adipose expansion. Alternatively, defect
in hyperplasia can be explained by limited adipocyte progenitor imposed by
ES-cell complementation. Since it has been shown that the pool of adipocyte
is finite in adult animals (Pajvani et al., 2005; Wojtanik et al., 2009), it can be
inferred that variation in ES-cell versus AZIP-cells makeup in this pool affects
adipogenic capacity of the animal. This is consistent with the observation
where higher degree of chimerism conferred to greater increase of body
weight after HFD. Consistently, AZIP-chimeras developed greater insulin
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FIGURE 5.10 Serum leptin versus body adiposity of AZIP(B6)chimeras measured by MRI. (A). Animals are fed on chow diet. Both
AZIP-and WT-chimeras have serum leptin level positively correlated with
adiposity. n=17 for AZIP-chimera and n=19 for WT-chimeras. (B). Animals
are fed on HFD. n=14 for AZIP-chimeras and n=11 for WT-chimeras.

resistance compared with WT-chimeras under HFD, consistent with previous
observation that limited expandability of adipose tissue is causative to
metabolic complication (Huang-Doran et al., 2010; Virtue and Vidal-Puig,
2008). However, low adiposity phenotype compared to WT-chimeras was
observed under both chow and high-fat diet cross all range of chimerism,
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suggesting that low contribution of ES-cell to the adipocyte per se cannot
fully account of the observed phenotype. Additional factors such as the
presence of AZIP-cells in the SVF can limit adipogenesis, including
accumulation of lipid during terminal differentiation, must be considered.
It has been a long debate whether hyperplasia contributes to obesity.
Hyperplasia is strongly correlated with severity of obesity, especially in
morbidly obese individuals (Hirsch and Batchelor, 1976). However, the data
was collected cross-sectionally, and therefore gives no direct information on
the longitudinal relationship between adiposity and adipocyte cellularity.
Therefore it is impossible to conclude whether the average increase in
adipocyte number seen in obese individuals is the result of adult adipocyte
recruitment or rather a reflection of a population of people predisposed (by
their pre-adulthood fat cell number) to obesity. At least in short-term studies,
adult humans do not show any increase in adipocyte number following
significant weight gain (Salans et al., 1971). Consistently, our data
demonstrated that resistance to obesity as a result of predisposed limited
adipocyte numbers, although complication from other tissues including the
SVF cannot be ruled out.
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TABLE 5.1 AZIP(FVB)-chimeric animals.
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5.3 Application
The presented blastocyst complementation assay provides a novel
platform to establish the role of specific molecules to regulate adipose tissue
mass in vivo. This is potentially a better alternative to the common employed
loxP-CRE system for the blastocyst complementation requires fewer breeding
and provides higher tissue specificity.
The most widely used adipocyte-specific CRE-mouse model has been
the aP2 promoter, which drives expression of fatty acid binding protein 4
(FABP4). However, in vitro studies have shown that aP2 is induced late in
adipogenesis (Bernlohr et al., 1985) and in vivo results have suggested that
aP2 is not expressed in adipocyte precursors (Rodeheffer et al., 2008). In
addition, the aP2-promoter expresses in other tissues during developments
such as macrophages and brain (Lee et al., 2013). Alternatively, AdiponectinCRE provides higher adipocyte-specificity, but it is also only expressed in
mature adipocytes (Jeffery et al., 2014). Lastly, PPARg-driven mouse model
has been shown to label adipogenic stromal cells in vivo (Tang et al., 2008),
yet its application is also limited stages in late adipogenesis. Most recently, a
novel preadipocyte factor, Zfp423, was identified as adipogenic marker both
in vitro and in vivo (Gupta et al., 2010; Gupta et al., 2012). Although Zfp423 is
expressed prior to aforementioned adipocyte factors in adipogenesis, its
specificity in vivo remained to be accessed. Indeed, as adipogenesis in vivo
and accompanying cell markers are poorly known, no suitable genetic mouse
model for studying preadipocytes have been constructed. With the AZIP-
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FIGURE 5.11 AZIP-blastocyst complementation as a method to
generate adipocyte specific knockout in one generation. Green and
red color depicts ES-cells that are labeled with different marker. Blue
triangle represents a homozygous knockout of a gene of interest,
presumably generated by CRISPR mediated genome modification.

chimera model, adipocyte specific gene modifications can be achieved in one
step by introducing gene targeted mutations into the donor ES cells (FIGURE
5.11). As such, gene modification is achieved in early progenitor cells, which
is very useful to study the genetics of adipose tissue development in vivo.
However, the current AZIP-chimera model is limited in several
regards. First, since AZIP-transgene is driven by aP2-promoter, tissue
specificity remains concerning. Additionally, since any complementing effect,
in theory, cannot be assayed before the expression of AZIP-transgene, defects
in early adipocyte stages remain masked. Secondly, the moderate
lipodystrophy observed in AZIP-chimeras complemented with wild-type ES
cells is indicative of inherent developmental defects of cultured ES-cells. It
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has been shown that cultured ES-cells accumulate epigenetic modifications
that affect in vivo development (Eckardt et al., 2011). Even if a specific ES-cell
clone has been proven pluripotent (defined as capable of producing live born
through tetraploid complementation), it could be a result of developmental
compensation and that it does not provide direct information on its
developmental capacity under normal conditions. In addition, AZIPblastocyst is likely developmentally dominant over ES-cells. Although the
mechanistic details are unclear, it has been shown that, through inter-species
blastocyst complementation, the blastocyst host is instructive in determine
overall animal size and organ morphology in interspecies chimeras (Solter,
2010). As such, it is likely that the developmental potential of wild-type EScells in terms of its adipogenic capacity is limited by AZIP-blastocyst. Two
possible strategies can circumvent this limitation. First, aggregation chimeras
using two embryos will address the concern of developmental discrepancy
between live embryo and cultured cells. Second, reverse the combination of
blastocyst and ES-cell by injecting AZIP-transgenic ES-cells into wild-type
blastocysts. This provides additional advantage of lightening up the breeding
load on AZIP-animals, which has compromised fertility.
Despite having limitation in studying adipocyte development, we plan
to apply blastocyst complementation method to characterize the in vivo
functions of novel factors involved in leptin regulation. As described in
Chapter 3, we mapped the cis-elements that regulate leptin expression in vivo
using leptin-luciferase reporter mice. Combining biochemical assays and
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genome-wide bioinformatics, we have identified several candidate transfactors that interact with these sequences. In Chapter 5, we have performed
RNA-sequencing on leptin specific gene expression pattern, upon which we
have identified different genes co-regulated with leptin. These data provided
gene candidate that can be subject to generating ES-cell knockout using
CRISPR technique (Wang et al., 2013a). The presented blastocyst
complementation assay will be useful in generating adipocyte-specific
knockout of these candidates in one generation and reveal their in vivo
function in adipose tissue.
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CHAPTER 6: CONCLUSION
Since the discovery of leptin in 1994, a staggering amount of effort has
advanced our understanding of leptin’s critical role in the regulation of
energy homeostasis and glucose metabolism. Yet the molecular and cellular
mechanisms regulating leptin production in adipose tissue have remained as
a gap in knowledge. In the face of the growing prevalence of obesity, the
molecular basis of adipose tissue expansion in response to diet-induced
obesity is a pressing question for disease management. While leptin serves as
the afferent signal of a feedback system for regulating energy homeostasis,
common obesity are characterized by leptin resistance developed from
chronic hyperleptinemia. Understanding the mechanism of increase leptin
production in response to increase adiposity is therefore fundamental to
study of pathogenesis of obesity. Since serum leptin correlates with body
adiposity and correlates with mRNA levels in each adipocyte, it was
hypothesized that leptin expression is regulated by an adipocyte cellautonomous mechanism that senses lipid content within adipocytes.
Lack of a suitable cell culture model to study leptin regulation
compounded with a lack of understanding of adipose tissue development in
vivo had made the study of leptin regulation in vivo particularly challenging.
We address this by developing a luciferase BAC-transgenic reporter mouse
model that allows us to assay qualitative and quantitative leptin expression
in vivo. In Chapter 3, using a series of reporter mice, we first narrowed down
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a 40kb region from -22kb to +18kb that is sufficient for quantitative and
qualitative leptin expression in vivo. We further demonstrated that the 5’end of this construct alone is sufficient for leptin transcriptional regulation.
Combination of sequence analysis and gel-shift assays identified a novel
distal cis-element of the leptin gene at -16.5kb that is essential for leptin
transcription. Since this cis-element contains a CCAAT-box sequence, a
candidate approach was taken in a super-shift assay and identified an
adipogenic factor, NF-Y, as the trans-element for this enhancer site.
To study the function of NF-Y in adipose tissue in vivo, we generated
lentiviral mediated knockdown of NF-Y in 3T3-L1 cells and generated
adipocyte specific NF-Y knockout mice via crossing adiponectin-CRE to NF-YA
fl/fl mice. These experiments, described in Chapter 4, consistently showed
that NF-Y is required for adipogenesis, since NF-Y knockdown 3T3-L1 cells
do not differentiate and NFY-KO mice showed progressive lipodystrophy.
NFY-KO mice were insulin resistant and dyslipidemic, both of which can be
ameliorated by leptin treatment. These results show that the metabolic
complications in NFY-KO mice are secondary to adipose tissue loss cause by
the deletion. Unfortunately, leptin expression is reduced in NFY-KO mice but
likely as a result of lipodystrophy. To study the direct function of NF-Y in
leptin transcriptional regulation in vivo, an inducible model such as the
adiponectin-ER-CRE system can be considered. Alternatively, deletion or
point mutation of the -16.5kb cis-element directly in the genome, which is
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made accessible with CRISPR technique, may provide insight to the
endogenous function of this regulatory sequence.
While the leptin-luciferase transgenic model proved to be an excellent
tool in identifying cis-elements within the leptin gene, there is no good
unbiased method in identifying the corresponding trans-factors. We address
this by performing RNA-sequencing experiments in adipose tissue with
animals under varying ambient leptin. Leptin treatment, in both wild-type
and ob/ob mice, produces unique metabolic effects that result in fat loss. As
such, it is postulated that gene expression profiles vary with leptin
expression levels and that by comparing among samples, one can identify
molecular and cellular profiles that modulate leptin expression. Sequencing
experiments were performed with untreated wild-type, ob/ob, wild-type
leptin withdrawal (model of acute leptin deficiency), and ob/ob leptin
replacement (model of leptin induced weight loss). Coupled with other
genomic methods such as the DNAse hypersensitivity assay and ChIP-seq
assay, we aim to understand the transcriptional network modulated by leptin
levels in white adipose tissue. This part of study is under progress.
Lastly, we took the developmental approach to study leptin regulation
in vivo. Adipose tissue is the most plastic organ in the body, of which the size
is determined by coordinated processes between hypertrophy and
hyperplasia. Regarding adipose tissue as an endocrine organ for leptin and
other adipokines, it is intriguing how organ size control is achieved. We
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performed an AZIP-blastocyst complementation experiment to study
developmental control of adipose tissue and leptin regulation. The unique
property of blastocyst complementation allows the distinction between
adipocyte autonomous versus non-autonomous factors that contribute to
determine body adiposity and regulate metabolic functions. Specifically,
because the AZIP-blastocyst cannot develop into mature adipocytes, all
mature adipocytes were progenies of wild-type ES cells in the chimeric
animals. As such, we first showed that adipocyte progenitor number as
represented by degree of chimerism does not affect adiposity in adult
chimeras in chow diet. Nonetheless, at least in the case of B6 background,
AZIP-chimeras are partially lipodystrophic with moderate insulin resistance.
Moreover, AZIP-chimeras with low chimerism were unable to expand
adipose tissue upon HFD challenge, suggesting that hyperplastic expansion is
required to accommodate excess dietary fat. Adipose tissue expansion is
critical to metabolic health, as excess lipid that cannot be stored in adipose
tissue results in lipotoxicity and insulin resistance in other peripheral tissues.
Overall, an incomplete rescue of AZIP-phenotype by ES-cell complementation
showed that the broad spectrum of metabolic health is controlled by intricate
mechanisms involving other cell types and tissues. Nonetheless, under both
chow and HFD conditions, serum leptin is correlated with body adiposity,
suggesting adipocyte-autonomous regulation of leptin transcription.
Altogether, this thesis presents the molecular basis as well as the
cellular basis of leptin regulation by using different mouse models. Leptin127

luciferase BAC transgenic mice can be applied to the study of acute leptin
regulation by live luciferase imaging following pharmaceutical or genetic
manipulations. The AZIP-blastocyst complementation model is useful in
generating adipocyte specific knockout within one generation, avoiding time
consuming crossing with the traditional genetic approach. Both models will
be instrumental in further elucidating the molecular and cellular mechanisms
regulating leptin gene expression in adipose tissue in vivo.
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